<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Surgical resection of lesions of the head of the pancreas
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Surgical resection of lesions of the head of the pancreas
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Surgical resection of lesions of the head of the pancreas
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard A Reber, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stanley W Ashley, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H176949472">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resection of the head of the pancreas is indicated primarily for neoplasms and necessitates concomitant duodenal resection. It is typically accomplished with a pancreaticoduodenectomy, which may also be performed to manage pancreatic or duodenal trauma and chronic pancreatitis.
        </p>
        <p>
         Pancreaticoduodenectomy is a complex, high-risk surgical procedure. The lowest operative mortality rates and best long-term cancer outcomes have been demonstrated at high-volume centers [
         <a href="#rid1">
          1,2
         </a>
         ]. In experienced hands, the median operative time for the Whipple procedure is 5.5 hours, with a median blood loss of 350 mL and mortality of less than 4 percent [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The perioperative management and general techniques for resection of the head of the pancreas are reviewed here. An overview of the surgical management of cancers involving the exocrine pancreas is presented in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2482.html" rel="external">
          "Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis"
         </a>
         .)
        </p>
        <p>
         The techniques for resection of the body and tail of the pancreas are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5660.html" rel="external">
          "Surgical resection of lesions of the body and tail of the pancreas"
         </a>
         .)
        </p>
        <p>
         The techniques of resection of sporadic pancreatic neuroendocrine tumors are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15045.html" rel="external">
          "Surgical resection of sporadic pancreatic neuroendocrine tumors"
         </a>
         .)
        </p>
        <p>
         Surgery for chronic pancreatitis is discussed in another dedicated topic. (See
         <a class="medical medical_review" href="/z/d/html/15109.html" rel="external">
          "Surgery for chronic pancreatitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949496">
         <span class="h1">
          INDICATIONS FOR PANCREATIC HEAD RESECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common indication for resection of the head of the pancreas is the presence of a malignant or premalignant neoplasm of the pancreas or one of the other periampullary structures (bile duct, ampulla, or duodenum) [
         <a href="#rid4">
          4-6
         </a>
         ]. Certain types of neoplasms may be amenable to local excision (enucleation), and some benign conditions may also require pancreatic head resection (eg, trauma, chronic pancreatitis).
        </p>
        <p>
         Specific indications for pancreatic head resection include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pancreatic
         <strong>
         </strong>
         adenocarcinoma (see
         <a class="medical medical_review" href="/z/d/html/2482.html" rel="external">
          "Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ampullary carcinoma (see
         <a class="medical medical_review" href="/z/d/html/655.html" rel="external">
          "Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ampullary adenoma (see
         <a class="medical medical_review" href="/z/d/html/649.html" rel="external">
          "Ampullary adenomas: Management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroendocrine tumors (see
         <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">
          "Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cholangiocarcinoma (see
         <a class="medical medical_review" href="/z/d/html/2467.html" rel="external">
          "Adjuvant and neoadjuvant therapy for localized cholangiocarcinoma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Duodenal neoplasm (see
         <a class="medical medical_review" href="/z/d/html/2509.html" rel="external">
          "Treatment of small bowel neoplasms"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combined pancreatic/duodenal injury (see
         <a class="medical medical_review" href="/z/d/html/15144.html" rel="external">
          "Management of duodenal trauma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116260.html" rel="external">
          "Management of pancreatic trauma in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic pancreatitis (see
         <a class="medical medical_review" href="/z/d/html/5647.html" rel="external">
          "Chronic pancreatitis: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15109.html" rel="external">
          "Surgery for chronic pancreatitis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H176949508">
         <span class="h1">
          PREOPERATIVE EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H176949514">
         <span class="h2">
          Medical assessment and optimization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with indications for resecting the head of the pancreas frequently have significant medical comorbidities. Since most pancreatic resections are performed under elective circumstances, there should be adequate time to assess risk factors and optimize the patient's medical status.
        </p>
        <p>
         Preoperative medical assessment is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2793.html" rel="external">
          "Preoperative evaluation and management of patients with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">
          "Evaluation of cardiac risk prior to noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6917.html" rel="external">
          "Evaluation of perioperative pulmonary risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4816.html" rel="external">
          "Preoperative medical evaluation of the healthy adult patient"
         </a>
         .)
        </p>
        <p>
         For patients taking antiplatelet therapy for primary or secondary prevention of cardiovascular disease, or other indications, we generally stop
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and full
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (325 mg) for at least one week before surgery but allow patients to continue to take baby aspirin (81 mg). Although cessation of aspirin prior to elective pancreatic surgery has been done routinely, evidence suggests that this may not be necessary. In a retrospective review of 1017 patients undergoing pancreas resection, 28.4 percent were maintained on aspirin therapy throughout the perioperative period [
         <a href="#rid7">
          7
         </a>
         ]. Among these patients, 699 underwent pancreaticoduodenectomy, 204 in the aspirin group and 484 in the nonaspirin group. Overall, there were no significant differences between the aspirin and nonaspirin groups for intraoperative blood loss, rate of blood transfusion, or other major procedure-related complications. The aspirin group had a slightly increased rate of cardiovascular complications, but the difference was not significant (10.1 versus 7 percent). (See
         <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">
          "Perioperative medication management", section on 'Aspirin'
         </a>
         .)
        </p>
        <p>
         Although many of these patients have lost weight, most are still adequately nourished to safely undergo the pancreatic head resection. However, if the serum albumin is &lt;3 g/dL, or if surgery must be delayed for more than two weeks, we prescribe supplemental nutrition [
         <a href="#rid8">
          8
         </a>
         ]. Nutrition can usually be provided enterally (Ensure, or another similar preparation according to patient preference, for five days before the operation), but on occasion
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         may be needed. (See
         <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">
          "The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'The perioperative setting'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">
          "The role of parenteral and enteral/oral nutritional support in patients with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support", section on 'Indications'
         </a>
         .)
        </p>
        <p>
         Once a decision has been made to proceed with surgery, the patient should be informed of the potential for surgical complications, as well as the possibility that pancreatic resection may not be possible if unrecognized metastatic or locally advanced unresectable disease is identified.
        </p>
        <p class="headingAnchor" id="H176949520">
         <span class="h2">
          Preoperative biliary drainage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with pancreatic cancer who are jaundiced are at risk for associated coagulopathy, malabsorption, and malnutrition. It was hoped that relief of biliary obstruction preoperatively would correct these defects and decrease postoperative morbidity and mortality rates. However, results from randomized trials have not been consistent. Uncertainty as to the benefit of preoperative biliary drainage has led to differing approaches. Some surgeons routinely decompress jaundiced patients with an endoscopically placed stent prior to surgery. However, most surgeons (including the author) reserve biliary decompression for patients whose serum bilirubin concentration exceeds 20 mg/dL, for those in whom surgery will be delayed for longer than two weeks, and in those with debilitating pruritus or cholangitis.
        </p>
        <p>
         Although animal studies suggest that biliary drainage prior to pancreatic resection improved surgical outcomes, clinical studies in humans have not consistently shown a benefit. Multiple randomized trials have been conducted in patients with potentially resectable pancreatic cancer and malignant obstructive jaundice, with one suggesting benefit for preoperative biliary drainage [
         <a href="#rid9">
          9
         </a>
         ], five no benefit [
         <a href="#rid10">
          10-14
         </a>
         ], and three potential harm [
         <a href="#rid10">
          10,11,15
         </a>
         ]. An earlier Cochrane review had concluded that stented patients had significantly fewer postoperative complications but similar postsurgical mortality [
         <a href="#rid16">
          16
         </a>
         ]. However, this analysis did not include data from the subsequent largest randomized trial of preoperative biliary drainage versus no drainage in 202 patients with cancer of the head of the pancreas, which showed a nonsignificant trend toward more surgery-related complications with preoperative biliary drainage (47 versus 37 percent, relative risk 0.79, 95% CI 0.57-1.11) [
         <a href="#rid15">
          15
         </a>
         ]. Later meta-analyses identified six trials (mostly patients with malignant obstructive jaundice, but some with benign disease) and included the larger, later trial in patients with pancreatic cancer [
         <a href="#rid17">
          17-19
         </a>
         ]. Again, no significant differences in mortality were seen, but overall serious morbidity was higher in the preoperative drainage group (60 per 100 patients versus 26 per 100 patients).
        </p>
        <p>
         When stenting is chosen for jaundiced patients who will undergo pancreatic head resection, the type of stent placed should be reviewed with the surgeon prior to placement. We suggest a plastic biliary stent (≥10 French), keeping the proximal end of the stent at or below the level of the cystic duct takeoff. Metallic stents often incite a severe inflammatory reaction and may be incorporated into the bile duct wall, making them difficult to remove at the time of surgery. A metal stent that is placed too high into the common bile duct can complicate the surgery, although this is less of a concern when the latest covered metal stents are used. However, some surgeons have not found significant adverse effects using self-expanding metallic stents [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13925.html" rel="external">
          "Endoscopic stenting for malignant biliary obstruction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H198290625">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should undergo preoperative imaging that includes multiphasic high-resolution pancreatic protocol computed tomography (CT) with 1 to 2 mm cuts through the pancreas during the early arterial phase and venous phase [
         <a href="#rid21">
          21-27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4051544703">
         <span class="h3">
          Staging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative imaging evaluation to assess resectability [
         <a href="#rid28">
          28
         </a>
         ], the role of endoscopic ultrasound (EUS), and radiographic staging are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2501.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer", section on 'Imaging studies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5638.html" rel="external">
          "Endoscopic ultrasound in the staging of exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949526">
         <span class="h3">
          Vascular evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine preoperative CT helps to identify hepatic vascular anatomy and prepares the surgeon for any potential vascular anomalies that may be present [
         <a href="#rid29">
          29
         </a>
         ]. The most common aberration in hepatic arterial anatomy is the replaced right hepatic artery arising from the superior mesenteric artery  (
         <a class="graphic graphic_figure graphicRef56984" href="/z/d/graphic/56984.html" rel="external">
          figure 1
         </a>
         ). Every attempt should be made to preserve the aberrant vessel unless its resection is oncologically indicated.
        </p>
        <p>
         In addition, preoperative CT can detect hemodynamically significant mesenteric arterial stenosis. If needed, significant mesenteric arterial stenosis can be treated with a stent to minimize the potential for postoperative ischemic complications [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         In patients with pancreatic cancer for whom vascular resection is thought to be beneficial, preoperative consultation with a vascular surgeon is ideal to assist with the preoperative vascular evaluation, identify appropriate vascular conduit, and allow coordinated operative scheduling. The experienced surgical oncologist may undertake vascular resection and replacement without assistance, but having a vascular surgeon on standby is prudent. (See
         <a class="local">
          'Vein excision and reconstruction'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2482.html" rel="external">
          "Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis", section on 'Vascular resection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949532">
         <span class="h1">
          PREPARATION
         </span>
        </p>
        <p class="headingAnchor" id="H176949538">
         <span class="h2">
          Bowel preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We instruct patients to eat normally prior to surgery with standard cessation of oral intake beginning at midnight prior to the operation as determined by the American Society of Anesthesiology guidelines. Bowel preparation is not necessary prior to pancreatic resection. (See
         <a class="medical medical_review" href="/z/d/html/15261.html" rel="external">
          "Overview of colon resection", section on 'Bowel preparation'
         </a>
         .)
        </p>
        <p>
         One small randomized trial did not identify any beneficial effects for preoperative probiotics or selective decontamination [
         <a href="#rid31">
          31
         </a>
         ]. These were not found to have any influence on bacterial translocation, intestinal permeability, or inflammatory mediator expression.
        </p>
        <p class="headingAnchor" id="H176949544">
         <span class="h2">
          Antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         We routinely give prophylactic antibiotics before pancreaticoduodenectomy. The first dose is given before the incision is made, and the last dose is given on the evening of the day of operation. The choice of antibiotics should be based on local hospital data that reflect characteristic bacterial pathogens  (
         <a class="graphic graphic_table graphicRef65369" href="/z/d/graphic/65369.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">
          "Antimicrobial prophylaxis for prevention of surgical site infection in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13984.html" rel="external">
          "Antimicrobial prophylaxis for prevention of surgical site infection following gastrointestinal procedures in adults"
         </a>
         .)
        </p>
        <p>
         In a North American randomized trial of 778 patients undergoing pancreaticoduodenectomy, prophylactic
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         reduced 30-day surgical site infection rate from 33 to 20 percent compared with
         <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">
          cefoxitin
         </a>
         (one of the current prophylactic antibiotics choices  (
         <a class="graphic graphic_table graphicRef65369" href="/z/d/graphic/65369.html" rel="external">
          table 1
         </a>
         )) [
         <a href="#rid32">
          32
         </a>
         ]. Patients who received piperacillin-tazobactam also had a lower rate of postoperative sepsis (4.2 versus 7.5 percent),
         <em>
          Clostridioides difficile
         </em>
         colitis (0.3 versus 3.5 percent), and clinically relevant postoperative pancreatic fistula (13 versus 19 percent). This trial was terminated early after the second scheduled interim analysis, and no intraoperative bile culture was obtained.
        </p>
        <p>
         Some have speculated that antibiotics based upon the results of bile cultures obtained at the time of preoperative biliary stenting or intraoperatively would decrease the incidence of infectious complications following pancreaticoduodenectomy [
         <a href="#rid31">
          31,33-35
         </a>
         ]. In a meta-analysis of seven studies, targeted antibiotics were associated with a significantly lower rate of overall postoperative surgical site infections (risk ratio 0.55, 95% CI 0.37-0.81), superficial/deep incisional site infections (risk ratio 0.33, 95% CI 0.18-0.59), and organ space site infection (risk ratio 0.54, 95% CI 0.38-0.76) compared with standard antibiotic therapy [
         <a href="#rid36">
          36
         </a>
         ]. Targeted antibiotics (eg,
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         or ampicillin-clavulanic acid) typically cover both
         <em>
          Enterococcus
         </em>
         and
         <em>
          Enterobacter
         </em>
         species.
        </p>
        <p>
         For patients found to have bacteriobilia, the duration of antibiotic therapy remains in question. In a retrospective review of 197 patients who underwent pancreaticoduodenectomy, patients in a "control" group received only perioperative prophylactic antibiotics and were compared with a "treatment" group who were continued on antibiotics until intraoperative bile culture results became available [
         <a href="#rid35">
          35
         </a>
         ]. In the "treatment" group, patients with bacteriobilia received 10 days of antibiotic treatment, which was otherwise discontinued in patients without bacteriobilia. Treatment of bacteriobilia was associated with a decreased rate of postoperative wound infections compared with only perioperative antibiotics in the "control" group (3 versus 12 percent). However, fewer patients in the control group had undergone preoperative biliary stenting (48 versus 67 percent), but a higher number of intraperitoneal drains were placed at the time of resection in the control group (85 versus 38 percent).
        </p>
        <p class="headingAnchor" id="H176949550">
         <span class="h2">
          Thromboprophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend pharmacologic thromboprophylaxis for patients undergoing pancreaticoduodenectomy. We also place intermittent pneumatic compression devices prior to induction and continue their use until the patient is ambulatory.
        </p>
        <p>
         Patients undergoing pancreaticoduodenectomy are at moderate-to-high risk for venous thromboembolism due to the nature of the surgery (major open surgery &gt;45 minutes)  (
         <a class="graphic graphic_table graphicRef83739" href="/z/d/graphic/83739.html" rel="external">
          table 2
         </a>
         ). The presence of malignancy increases the risk, which may require an extended period of pharmacologic thromboprophylaxis [
         <a href="#rid37">
          37
         </a>
         ]. Patients with pancreatic adenocarcinoma have an even greater risk for venous thromboembolism than patients with other common adenocarcinomas [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The choice and suggested duration of pharmacologic thromboprophylaxis are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
         A small retrospective study of patients undergoing pancreatic surgery for malignancy found that the percentage of patients with venous thromboembolism decreased from 17.6 to 2.6 percent after implementation of a protocol that encouraged preoperative pharmacologic prophylaxis (5000 units of subcutaneous heparin) by including it in the preoperative checklist [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H176949556">
         <span class="h1">
          SURGICAL PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H176949568">
         <span class="h2">
          Staging laparoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small hepatic or peritoneal metastases, which are not evident from the preoperative studies, may be found at surgical exploration in 8 to 15 percent of cases. As an example, 117 of 1423 pancreatectomies (8 percent) intended for resection of pancreatic ductal adenocarcinoma were aborted, most often due to occult liver (79 percent) or peritoneal metastasis (16 percent) [
         <a href="#rid40">
          40
         </a>
         ]. For this reason, some surgeons prefer to begin cancer operations with laparoscopy, which permits examination of the liver and peritoneal surfaces and biopsy of any suspicious areas. If a metastatic tumor is found, laparotomy may be avoided. (See
         <a class="medical medical_review" href="/z/d/html/2501.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer", section on 'Staging laparoscopy'
         </a>
         .)
        </p>
        <p>
         For patients undergoing pancreatic head resection, a drawback of staging laparoscopy is the additional time and expense required for the laparoscopic instrumentation and the inability to determine whether any vascular invasion has occurred that would preclude an attempt at resection. Thus, we restrict the use of laparoscopy to cases where there is a high likelihood of unresectability that has not been confirmed preoperatively. Examples include some patients with pancreatic head cancer and computed tomography (CT) evidence of liver surface or other intraperitoneal metastases that have not been proven with biopsy, and patients with pancreatic head cancer and ascites, which is probably due to unrecognized peritoneal metastases. In a retrospective study of occult metastatic disease in pancreatic ductal adenocarcinoma, independent predictors include indeterminate lesions on preoperative CT, tumor size &gt;30 mm, abdominal pain, and preoperative CA 19-9 greater than 192 U/mL [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         If unresectable disease is found at the time of laparoscopy and the patient has unrelieved obstructive jaundice or is at risk for gastric outlet obstruction, we perform a palliative gastric and/or biliary bypass laparoscopically in most cases [
         <a href="#rid41">
          41
         </a>
         ]. Although postoperative endoscopic placement of a metal biliary stent is an acceptable alternative to operative biliary bypass, it does not work for all patients and is associated with its own complications. (See
         <a class="local">
          'Palliative surgery'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer", section on 'Jaundice'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949574">
         <span class="h2">
          Lymphadenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard regional lymph node basin for tumors located in the head and neck of the pancreas includes those along the common bile duct; common hepatic artery; portal vein; pyloric, posterior, and anterior pancreaticoduodenal arcades; and along the superior mesenteric vein and right lateral wall of the superior mesenteric artery  (
         <a class="graphic graphic_figure graphicRef96774" href="/z/d/graphic/96774.html" rel="external">
          figure 2
         </a>
         ). It is important to identify and properly assess as many regional lymph nodes in the specimen as possible. Based on survival data, evaluation of a minimum of 12 lymph nodes is recommended to accurately stage N0 tumors [
         <a href="#rid42">
          42
         </a>
         ]. The total number of positive lymph nodes is now used to classify the N category of the TNM (Tumor, Node, Metastasis) classification according to the 8
         <sup>
          th
         </sup>
         edition of the American Joint Committee on Cancer (AJCC) cancer staging manual. Metastasis in one to three regional lymph nodes is N1 disease, while metastasis in four or more regional lymph nodes is N2 disease  (
         <a class="graphic graphic_table graphicRef111135" href="/z/d/graphic/111135.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         Tumor involvement outside of this regional basin is considered distant metastasis. There is no evidence to support benefit from extended lymphadenectomy [
         <a href="#rid43">
          43
         </a>
         ], and we do not perform extended lymph node dissection. As an example, we biopsy any enlarged or suspicious aortocaval lymph nodes and abort the pancreaticoduodenectomy if the biopsy is positive on frozen section. (See
         <a class="medical medical_review" href="/z/d/html/2482.html" rel="external">
          "Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis", section on 'Extent of lymphadenectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949580">
         <span class="h2">
          Vein excision and reconstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancreaticoduodenectomy with portal vein (PV) or superior mesenteric vein (SMV) resection and reconstruction should be considered a standard approach for pancreatic adenocarcinomas that focally involve the PV or SMV, provided that adequate inflow and outflow veins are present, the tumor does not involve the superior mesenteric artery or hepatic artery, and an R0 resection can be accomplished [
         <a href="#rid44">
          44
         </a>
         ]. Nevertheless, many surgeons, including the author, prefer to treat patients with PV or SMV involvement with neoadjuvant systemic chemotherapy for at least six months before the operation is performed, as it increases the R0 resection rate and overall survival [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2482.html" rel="external">
          "Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis", section on 'Vascular resection'
         </a>
         .)
        </p>
        <p>
         In a single-center study from Norway, 16 percent of 784 patients who underwent pancreaticoduodenectomy required vein excision and reconstruction [
         <a href="#rid46">
          46
         </a>
         ]. Both operative time (422 versus 312 minutes) and blood loss (700 versus 500 mL) were increased with vein resection. Severe postoperative complications were also more prevalent after vein resection, with one in four patients requiring relaparotomy (most commonly for bleeding). This reoperation rate is higher than reported in the literature for this group of patients; a meta-analysis of 17 studies reported an average reoperation rate of 12 percent (range 0 to 48 percent) [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         The techniques of vein reconstruction vary and should be guided by preoperative evaluation of vascular involvement [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H176949586">
         <span class="h2">
          Drainage of the pancreatic bed
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drain placement after pancreatic resection remains common [
         <a href="#rid49">
          49,50
         </a>
         ]. The rationale for leaving a drain after a pancreaticoduodenectomy is to provide controlled external drainage of a pancreatic leak. Inadequate drainage of a leak can lead to an intra-abdominal abscess.
        </p>
        <p>
         However, the routine use of intra-abdominal drains after pancreaticoduodenectomy is controversial [
         <a href="#rid50">
          50-52
         </a>
         ]. While several observational studies [
         <a href="#rid44">
          44,53-56
         </a>
         ] and two randomized trials [
         <a href="#rid57">
          57,58
         </a>
         ] failed to demonstrate any benefit of drain placement, another trial reported that drain placement lowered the morbidity and mortality rates as well as the severity of complications in patients who underwent pancreatic resection [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         A 2018 Cochrane meta-analysis of four randomized trials suggested that routine abdominal drainage probably reduced mortality slightly at 90 days (moderate-quality evidence), that use of an active drain compared with the use of a passive drain may slightly reduce the length of hospital stay (low-quality evidence), and that early removal may be superior to late removal for people with low risk of postoperative pancreatic fistula [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Thus, until better evidence becomes available, we suggest that drains be placed selectively following pancreatic resection in patients who are at a high risk of developing pancreatic fistula (eg, those with a soft and friable pancreas, those with a small [&lt;2 mm] pancreatic duct) and that drains be removed early when there is no evidence of fistula development. (See
         <a class="local">
          'Drain management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H176949592">
         <span class="h1">
          PANCREATICODUODENECTOMY
         </span>
        </p>
        <p class="headingAnchor" id="H1442419967">
         <span class="h2">
          Conventional versus modified pancreaticoduodenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard operation for pancreatic cancer within the head or uncinate process of the pancreas is pancreaticoduodenectomy. Modifications of conventional pancreaticoduodenectomy (ie, Whipple procedure) have been developed in an attempt to improve outcomes or minimize the morbidity associated with the operation. These include the pylorus-preserving pancreaticoduodenectomy and subtotal stomach-preserving pancreaticoduodenectomy.
        </p>
        <p>
         The available data suggest that, for suitable cases, perioperative morbidity and mortality and long-term survival are not affected by the use of pylorus-preserving techniques [
         <a href="#rid61">
          61,62
         </a>
         ]. The impact of a pylorus-preserving approach on gastrointestinal function remains an open question, but most agree that the incidence of delayed gastric emptying is not increased when compared with the conventional operation. (See
         <a class="local">
          'Delayed gastric emptying'
         </a>
         below.)
        </p>
        <p>
         Given the potential time savings, lower rate of blood loss, and similar oncologic outcomes, we perform a pylorus-preserving pancreaticoduodenectomy on almost all of our patients [
         <a href="#rid61">
          61,63
         </a>
         ]. However, a conventional pancreaticoduodenectomy (Whipple) operation should be performed if the tumor involves the proximal duodenum, pylorus, or gastric antrum.
        </p>
        <p class="headingAnchor" id="H176949598">
         <span class="h3">
          Conventional pancreaticoduodenectomy (Whipple)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conventional pancreaticoduodenectomy involves removal of the pancreatic head, duodenum, first 15 cm of the jejunum, common bile duct, and gallbladder, and a partial gastrectomy  (
         <a class="graphic graphic_figure graphicRef120316" href="/z/d/graphic/120316.html" rel="external">
          figure 3A
         </a>
         ).
        </p>
        <p>
         Pancreaticoduodenectomy is accomplished in an orderly fashion, usually in the following sequence.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The abdomen is assessed for metastatic disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The duodenum and the head of the pancreas are mobilized, and the superior mesenteric vein is isolated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The stomach and remainder of duodenum are mobilized and the proximal extent of the resection is determined.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The structures of the porta hepatis are skeletonized.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The gallbladder is removed and the common hepatic duct is transected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The proximal jejunum is mobilized and transected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The neck of the pancreas is transected and the remaining attachments of the specimen to the superior mesenteric vein, portal vein, and the superior mesenteric artery are divided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal reconstruction is accomplished by providing drainage of the pancreatic stump and common hepatic duct, and restoring proximal and distal gastrointestinal continuity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H176949604">
         <span class="h3">
          Pylorus-preserving pancreaticoduodenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pylorus-preserving pancreaticoduodenectomy is a somewhat less radical operation that is being increasingly performed worldwide. The procedure preserves the gastric antrum, pylorus, and proximal 3 to 4 cm of the duodenum  (
         <a class="graphic graphic_figure graphicRef60689" href="/z/d/graphic/60689.html" rel="external">
          figure 4
         </a>
         ). Pylorus preservation may decrease the incidence of postoperative dumping and bile reflux gastritis that can occur in some patients undergoing partial gastrectomy.
        </p>
        <p>
         Several small randomized trials have directly compared a pylorus-preserving with a conventional pancreaticoduodenectomy in pancreatic or periampullary cancer, but with conflicting results [
         <a href="#rid64">
          64-71
         </a>
         ]. Data from uncontrolled studies are also conflicting [
         <a href="#rid72">
          72-75
         </a>
         ].
        </p>
        <p>
         A 2016 updated meta-analysis from the Cochrane database included eight trials that provided quantitative data on 512 patients [
         <a href="#rid61">
          61
         </a>
         ]. Heterogeneity among the trials was noted by the authors with respect to methodology and outcome parameters. The overall impact of a pylorus-preserving procedure on gastrointestinal function remains unclear. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There were no differences between the two procedures in terms of survival, postoperative mortality, and main morbidities (eg, pancreatic fistula, biliary leakage, or postoperative bleeding), except for delayed gastric emptying.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delayed gastric emptying was significantly more common after a pylorus-preserving procedure than after conventional surgery (31 versus 24 percent, odds ratio [OR] 3.03, 95% CI 1.05-8.70).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Operating time (weighted mean difference -45 minutes, 95% CI -75 to -16 minutes), red blood cell transfusion (weighted mean difference -0.47 units, 95% CI -0.86 to -0.07 units), and intraoperative blood loss (weighted mean difference -0.32 L, 95% CI -0.62 to -0.03 L) were all significantly reduced with the pylorus-preserving procedure.
        </p>
        <p>
        </p>
        <p>
         The technique for pylorus-preserving pancreaticoduodenectomy is described in a dedicated topic. (See
         <a class="medical medical_review" href="/z/d/html/5661.html" rel="external">
          "Pylorus-preserving pancreaticoduodenectomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949640">
         <span class="h3">
          Subtotal stomach-preserving pancreaticoduodenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subtotal stomach-preserving pancreaticoduodenectomy aims to preserve as much stomach as possible while minimizing problems related to delayed gastric emptying that are associated with preserving the pyloric ring in the face of vagal denervation [
         <a href="#rid76">
          76
         </a>
         ]. In this procedure, the duodenum, pylorus, and 1 to 2 cm of stomach are resected with the pancreatic specimen. Although described, this modification has yet to be validated, and it is uncommonly performed. Due to the retained antrum producing large amounts of gastrin, the incidence of gastric ulceration may be higher with stomach-preserving techniques compared with conventional pancreaticoduodenectomy.
        </p>
        <p>
         One study has retrospectively compared stomach-preserving with standard or pylorus-preserving pancreatoduodenectomy [
         <a href="#rid76">
          76
         </a>
         ]. Although the rate of delayed gastric emptying was marginally less for a stomach-preserving compared with a pylorus-preserving operation, there was no difference from conventional pancreaticoduodenectomy. One trial that compared a stomach-preserving with pylorus-preserving pancreaticoduodenectomy (50 patients in each group) found a reduced incidence of delayed gastric emptying for the stomach-preserving technique (10 versus 6 patients) [
         <a href="#rid77">
          77
         </a>
         ]. There were no differences in the rates of other complications.
        </p>
        <p class="headingAnchor" id="H176952475">
         <span class="h2">
          Gastrointestinal reconstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following resection, gastrointestinal reconstruction provides a drainage route for the remaining pancreas, the bile duct, and the stomach. A number of methods can be used to accomplish this, but most commonly the free end of jejunum is attached first to the pancreas, next to the bile duct, and last to the stomach or duodenal remnant  (
         <a class="graphic graphic_figure graphicRef120316" href="/z/d/graphic/120316.html" rel="external">
          figure 3A
         </a>
         ). Other techniques employ a separate Roux limb of jejunum to drain the stomach  (
         <a class="graphic graphic_figure graphicRef96650" href="/z/d/graphic/96650.html" rel="external">
          figure 3B
         </a>
         ), or the Roux limb can be used to drain the pancreas alone, while the proximal jejunum drains the bile duct and stomach.
        </p>
        <p class="headingAnchor" id="H176952960">
         <span class="h3">
          Pancreatic-enteric anastomosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Options for managing the pancreatic stump include a pancreaticojejunostomy (PJ)  (
         <a class="graphic graphic_figure graphicRef120316 graphicRef96650" href="/z/d/graphic/120316.html" rel="external">
          figure 3A-B
         </a>
         ) or a pancreaticogastrostomy (PG)  (
         <a class="graphic graphic_figure graphicRef101029" href="/z/d/graphic/101029.html" rel="external">
          figure 5
         </a>
         ). The choice is determined by surgeon preference as studies comparing the two techniques reported conflicting results.
        </p>
        <p class="headingAnchor" id="H4144363381">
         <span class="h4">
          Pancreaticojejunostomy versus pancreaticogastrostomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal method of pancreatic-enteric anastomosis is not clear. Some studies comparing PJ with PG show equivalency [
         <a href="#rid78">
          78-83
         </a>
         ]; others show that fewer postoperative fistulas develop after a PG [
         <a href="#rid78">
          78,84,85
         </a>
         ]. One of the largest trials, however, reported an increased rate of postoperative bleeding events after PG [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         A meta-analysis of seven randomized trials showed that PG resulted in significantly lower rates of pancreatic (11 versus 19 percent) and biliary fistulas (2 versus 5 percent) compared with PJ [
         <a href="#rid86">
          86
         </a>
         ]. A later Cochrane review of 10 trials, however, showed little or no difference between PG and PJ in rates of overall pancreatic fistula (21.4 percent PG versus 24.3 percent PJ), clinically significant pancreatic fistula (12.8 percent PG versus 19.3 percent PJ), or postoperative mortality (4.8 percent PG versus 3.9 percent PJ) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
         Based upon available data, some surgeons prefer pancreaticogastrostomy, especially when the pancreas is soft and friable, a condition associated with an increased risk of pancreatic fistula formation. Other surgeons who are experienced with and have had good personal results using pancreaticojejunostomy, however, are not likely to alter their practice [
         <a href="#rid78">
          78-82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4225383221">
         <span class="h4">
          Duct-to-mucosa versus invagination
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pancreaticojejunostomy, there are two predominant methods of reconstruction: end-to-side duct-to-mucosa anastomosis  (
         <a class="graphic graphic_figure graphicRef53080" href="/z/d/graphic/53080.html" rel="external">
          figure 6
         </a>
         ) or invagination of the pancreatic remnant [
         <a href="#rid88">
          88,89
         </a>
         ]. The invagination method can be performed either end-to-side or end-to-end  (
         <a class="graphic graphic_figure graphicRef106226" href="/z/d/graphic/106226.html" rel="external">
          figure 7
         </a>
         ) [
         <a href="#rid89">
          89,90
         </a>
         ]. The choice of the method is again determined by surgeon preference as there is no conclusive evidence to favor one method over the other.
        </p>
        <p>
         In a 2018 systematic review and meta-analysis of eight trials with a total of 1043 patients undergoing pancreaticojejunostomy after pancreaticoduodenectomy, there was no significant difference between the two anastomotic techniques in terms of overall and clinically relevant postoperative pancreatic fistula (POPF) rate, as well as secondary outcomes. Furthermore, the authors concluded that existing evidence is sufficient to conclude lack of difference and further trials on this subject matter are unlikely to change the outcome [
         <a href="#rid91">
          91
         </a>
         ]. A 2022 Cochrane review that included 11 trials reported similar findings [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H101607991">
         <span class="h4">
          Adjuncts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional techniques are aimed at reducing the incidence of postoperative pancreatic fistula formation. These include pancreatic stenting and application of tissue adhesives. However, study results are conflicted as to whether these adjuncts are helpful or not.
        </p>
        <p class="headingAnchor" id="H101607866">
         <span class="h5">
          Pancreatic stenting
         </span>
         <span class="headingEndMark">
          —
         </span>
         Placement of a pancreatic stent has the potential to decompress the main pancreatic duct and provide drainage of pancreatic secretions. However, the role of pancreatic stents in preventing pancreatic fistula is unclear. Available studies have important methodologic limitations. Until sufficient evidence is available, pancreatic stenting as a means to prevent postoperative pancreatic fistula following pancreaticoduodenectomy is according to surgeon preference.
        </p>
        <p>
         At least eight randomized trials have been conducted to investigate the role of pancreatic stenting in pancreaticoduodenectomy. An additional five randomized trials are ongoing, the results of which have not been reported. A 2016 Cochrane review of four trials [
         <a href="#rid93">
          93-96
         </a>
         ] found an overall reduction in the incidence of postoperative pancreatic fistulas for those who were stented compared with those who were not (20.7 versus 28.1 percent), but the difference was not statistically significant (risk ratio 0.67, 95% CI 0.39-1.14) [
         <a href="#rid97">
          97
         </a>
         ]. Another meta-analysis of five trials [
         <a href="#rid93">
          93-96,98
         </a>
         ] showed pancreatic stenting to have decreased the formation of clinically relevant fistulas (14.0 versus 25.8 percent, risk ratio 0.45, 95% CI 0.27-0.76).
        </p>
        <p class="headingAnchor" id="H101607978">
         <span class="h5">
          Tissue adhesives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies on the use of tissue adhesives, particularly fibrin glue, for prevention of postoperative pancreatic fistula have produced conflicting results [
         <a href="#rid99">
          99,100
         </a>
         ]. A 2020 Cochrane systemic review and meta-analysis of four randomized trials found that the effects of fibrin sealants on the prevention of postoperative pancreatic fistula are uncertain in people undergoing pancreaticoduodenectomy [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H176949670">
         <span class="h3">
          Biliary-enteric anastomosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The proper hepatic duct is typically drained into the same loop of jejunum that is used to drain the pancreas and the stomach through a hepaticojejunostomy  (
         <a class="graphic graphic_figure graphicRef120316 graphicRef96650" href="/z/d/graphic/120316.html" rel="external">
          figure 3A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/15167.html" rel="external">
          "Bile duct resection and reconstruction"
         </a>
         .)
        </p>
        <p>
         If the proper hepatic duct is smaller than 10 mm in diameter, a small T-tube may be inserted through the wall of the duct proximal to the anastomosis with the distal end of the T-tube placed through the anastomosis into the jejunal limb. An internal stent through the anastomosis is also satisfactory.
        </p>
        <p class="headingAnchor" id="H176949676">
         <span class="h3">
          Gastrointestinal anastomosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The manner in which gastrointestinal continuity is achieved depends upon the type of pancreaticoduodenectomy. In general, the stomach or duodenum (pylorus sparing) can be drained into the same proximal jejunal loop brought up to the right upper quadrant for the pancreatic and biliary anastomosis  (
         <a class="graphic graphic_figure graphicRef120316" href="/z/d/graphic/120316.html" rel="external">
          figure 3A
         </a>
         ), or to a separate Roux limb of more distal jejunum  (
         <a class="graphic graphic_figure graphicRef96650" href="/z/d/graphic/96650.html" rel="external">
          figure 3B
         </a>
         ). According to two randomized trials, there appear to be no significant differences in the incidence of postoperative pancreatic fistula [
         <a href="#rid102">
          102
         </a>
         ] or delayed gastric emptying [
         <a href="#rid103">
          103
         </a>
         ] whether the same loop or a separate Roux limb is used to drain the stomach/duodenum.
        </p>
        <p>
         When a single jejunal loop is used, the pancreatic and biliary anastomoses are placed 45 to 60 cm proximal to the gastrojejunostomy. This assures that the gastrojejunostomy is bathed in alkaline secretions, reducing the risk of stomal ulceration. However, it does not prevent reflux of gastric juice and food from the stomach into the biliary tree and pancreas, which can cause cholangitis if the limb is short or obstructed [
         <a href="#rid104">
          104-106
         </a>
         ]. Some surgeons add a Braun enteroenterostomy between the afferent and efferent limb to prevent or alleviate alkaline gastritis  (
         <a class="graphic graphic_figure graphicRef103470" href="/z/d/graphic/103470.html" rel="external">
          figure 8
         </a>
         ), but we doubt its usefulness.
        </p>
        <p>
         The gastrojejunostomy can be placed in front of the colon (antecolic, our preference) or behind the colon (retrocolic). Several small trials generated conflicting results regarding the incidence of delayed gastric emptying relative to the type of reconstruction [
         <a href="#rid107">
          107-111
         </a>
         ]. A 2022 Cochrane systematic review and meta-analysis found no differences between the two techniques with respect to morbidity (including delayed gastric emptying and pancreatic fistula), mortality, length of hospital stay, and quality of life [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1492457563">
         <span class="h2">
          Open versus minimally invasive
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancreaticoduodenectomy is a relative latecomer in the minimally invasive surgery revolution. The development of specialized instruments and technology was needed before minimally invasive pancreaticoduodenectomy was even technically feasible. Even with robotic techniques, minimally invasive pancreaticoduodenectomy is a complex operation that is suited for only selected patients in high-volume centers experienced with laparoscopic/robotic techniques [
         <a href="#rid113">
          113
         </a>
         ]. As with open surgery, mortality after minimally invasive pancreaticoduodenectomy was higher in low-volume hospitals than in high-volume hospitals (7.5 versus 3.4 percent), according to a meta-analysis of two registry studies that included close to 20,000 patients [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         A systematic review identified 27 retrospective studies that included close to 7000 patients undergoing pancreaticoduodenectomy (1306 minimally invasive, 5603 open) [
         <a href="#rid115">
          115
         </a>
         ]. Conversion to an open procedure was required in 0 to 40 percent of cases initially attempted laparoscopically [
         <a href="#rid116">
          116
         </a>
         ]. The minimally invasive approach was associated with longer operative times (mean difference [MD] 71 minutes, 95% CI 27-115) but lower intraoperative blood loss (MD -300 mL, 95% CI -400 to -200 mL). The rate of lymph node retrieval was significantly higher in the minimally invasive group (MD 1.34 nodes, 95% CI 0.14-2.53), and the likelihood of an R0 resection was also higher (OR 1.45, 95% CI 1.18-1.78). Hospital stay was significantly reduced for the minimally invasive group (MD -2.95 days, 95% CI -3.91 to -2 days). Minimally invasive pancreaticoduodenectomy was also associated with a reduction in postoperative hemorrhage (OR 1.60, 95% CI 1.03-2.49) and wound infection (OR 0.44, 95% CI 0.30-0.66), while the rate of overall mortality, reoperations, vascular resection, clinically relevant pancreatic fistula, delayed gastric emptying, and bile leak was similar between the groups.
        </p>
        <p>
         Three randomized trials have compared laparoscopic pancreaticoduodenectomy with the open procedure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first trial from India, which included 64 patients with periampullary tumors, largely echoed the findings of the above meta-analysis that laparoscopic pancreaticoduodenectomy required longer operative time but shorter hospital stay (13 versus 7 days) [
         <a href="#rid117">
          117
         </a>
         ]. Intraoperative blood loss was also reduced with laparoscopic surgery. Other short-term surgical and oncologic outcomes, including mortality, major morbidity, rates of fistula, delayed gastric emptying, and postoperative hemorrhage, lymph node yield, and rate of R0 resection, were all comparable between patients who underwent open versus laparoscopic pancreaticoduodenectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The second trial from Spain, which included 66 patients, associated laparoscopic pancreaticoduodenectomy with a shorter hospital stay (13.5 versus 17 days), fewer severe complications (5 versus 11 patients), and a more favorable postoperative course [
         <a href="#rid118">
          118
         </a>
         ]. Lymph node yield and resection margins were comparable between the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The third trial from the Netherlands (LEOPARD-2), which included 105 patients, found the opposite [
         <a href="#rid119">
          119
         </a>
         ]. Compared with open surgery, laparoscopic pancreaticoduodenectomy was associated with more major postoperative complications (50 versus 39 percent) and more complication-related mortalities (10 versus 2 percent) but no improvement in the rapidity of functional recovery (10 versus 8 days). Although these differences were not statistically significant, the trends were worrisome enough for the trial to be terminated early. Importantly, the trial was conducted in high-volume centers performing &gt;20 procedures annually, and all cases were performed by experienced surgeons.
        </p>
        <p>
        </p>
        <p>
         The only study comparing oncologic outcomes of laparoscopic versus open pancreaticoduodenectomy performed at a high-volume institution came from the Mayo Clinic [
         <a href="#rid120">
          120
         </a>
         ]. Faster recovery and shorter hospitalization associated with laparoscopic pancreaticoduodenectomy allowed earlier initiation of chemotherapy, but overall rates of chemotherapy and overall survival were unchanged.
        </p>
        <p>
         At some high-volume centers, robot-assisted pancreaticoduodenectomy has been adopted. The robotic platform allows for 3D vision, 540 degree wrist articulation, and tremor stabilization in addition to the conventional advantages of laparoscopy.
        </p>
        <p>
         Robotic-assisted pancreaticoduodenectomy has only been studied in nonrandomized comparative studies [
         <a href="#rid121">
          121-124
         </a>
         ]. A meta-analysis of 13 such studies found robotic pancreaticoduodenectomy to be associated with a longer operative time (by 71 minutes) but less blood loss (by 374 mL), shorter length of stay (by 5 days), and fewer wound infections than open surgery [
         <a href="#rid125">
          125
         </a>
         ]. Otherwise, the positive margin rate, number of lymph node harvested, and mortality, morbidity, reoperation, and readmission rates were all comparable between robotic and open procedures.
        </p>
        <p>
         Minimally invasive pancreatic surgery is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/127000.html" rel="external">
          "Minimally invasive pancreatectomy (MIP)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949682">
         <span class="h1">
          ENUCLEATION PROCEDURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some small (ie, ≤1 cm) benign lesions in the head of the pancreas can be enucleated, which avoids the need for pancreaticoduodenectomy. Enucleation should not be used when the lesion is large (usually &gt;2 cm) or when there is a chance that the lesion could be malignant. Larger lesions are associated with greater risk for pancreatic or bile duct injury, which could result in pancreatic or biliary fistula. If the lesion is malignant, enucleation does not remove surrounding soft tissue and lymph nodes, which may lessen the chance for cure and prevents adequate staging.
        </p>
        <p>
         Enucleation is most commonly performed for pancreatic neuroendocrine tumors, especially insulinomas. A retrospective study of neuroendocrine tumors (20 insulinomas and 6 gastrinomas), which compared tumor enucleation of the pancreatic head with pancreaticoduodenectomy, showed similar overall complication rates (69 versus 80 percent), but the rate of clinically relevant pancreatic fistulas was higher after enucleation (40 versus 14 percent) [
         <a href="#rid126">
          126
         </a>
         ]. The rate of reintervention and readmissions did not differ (49 versus 46 percent). However, the incidences of exocrine and endocrine insufficiency were significantly higher after pancreaticoduodenectomy (55 and 19 percent versus 5 and 7 percent).
        </p>
        <p>
         Prior to enucleation in patients with tumors close to the ductal system, preoperative placement of a pancreatic duct stent may help the surgeon to avoid ductal injury and to identify a major ductal disruption if it occurs. The technique for enucleation is described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5660.html" rel="external">
          "Surgical resection of lesions of the body and tail of the pancreas", section on 'Technique'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949688">
         <span class="h1">
          PALLIATIVE SURGERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the patient is found to have unresectable disease during the course of staging laparoscopy or during an attempted pancreaticoduodenectomy and downstaging neoadjuvant therapy is not an option (eg, liver or peritoneal metastases, very extensive local disease with complete major vascular occlusion, etc), surgical biliary and gastric bypass may be performed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prophylactic antecolic gastrojejunostomy should also be done in most patients who are likely to survive for more than three months. It does not add to the morbidity of the operation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biliary bypass (cholecysto- or choledochojejunostomy) effectively relieves biliary obstruction and eliminates the need for a subsequent biliary stent. If the gallbladder is used for the decompression, the surgeon should be certain that the cystic duct is open and is not likely to become obstructed by the tumor as it grows.
        </p>
        <p>
        </p>
        <p>
         In a contemporary series of over 600 pancreaticoduodenectomies, 17 percent were aborted [
         <a href="#rid127">
          127
         </a>
         ]. Palliative procedures in this cohort had far fewer complications (overall 17 percent, severe 9 percent) than historical series. Palliative procedures, however, delayed systemic therapy (median 47 versus 21 days), and 29 percent of patients never received additional treatments. Palliative procedures markedly decreased the need for future interventions (12 versus 79 percent). Intraoperative decisions regarding palliative procedures must incorporate the functional status and motivations of the patient; these procedures are increasingly safe but may still affect survival.
        </p>
        <p>
         Alternatively, in experienced centers, endoscopic relief of biliary obstruction is another less invasive but equally efficacious option. The details of endoscopic treatment for malignant pancreaticobiliary obstruction are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13925.html" rel="external">
          "Endoscopic stenting for malignant biliary obstruction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949694">
         <span class="h1">
          POSTOPERATIVE CARE AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients do not require intensive care unit monitoring following a pancreaticoduodenectomy. The majority of patients can be discharged within 7 to 10 days of the operation.
        </p>
        <p>
         We do not routinely use a nasogastric tube after surgery, which did not reduce major complication rate or length of stay compared with no nasogastric tube in a randomized trial [
         <a href="#rid128">
          128
         </a>
         ], and the patient is encouraged to ambulate early. (See
         <a class="medical medical_review" href="/z/d/html/15070.html" rel="external">
          "Inpatient placement and management of nasogastric and nasoenteric tubes in adults", section on 'Prophylactic placement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support"
         </a>
         .)
        </p>
        <p>
         Negative pressure wound therapy (NPWT) has been used by some in an attempt to reduce wound complications. We use it selectively only in patients at high risk for wound infection. A trial of 123 patients undergoing open pancreaticoduodenectomy found that applying negative pressure wound therapy to the (closed) surgical incision at the time of closure reduced surgical site infection by 69 percent (9.7 versus 31.1 percent) [
         <a href="#rid129">
          129
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4.html" rel="external">
          "Principles of abdominal wall closure", section on 'Negative pressure dressings'
         </a>
         .)
        </p>
        <p>
         Routine postoperative management is primarily focused on nutrition, the return of bowel function, and management of closed-suction drain output.
        </p>
        <p class="headingAnchor" id="H2712643">
         <span class="h2">
          Nutrition support
         </span>
         <span class="headingEndMark">
          —
         </span>
         We prefer to feed patients orally after a pancreaticoduodenectomy, if possible, rather than via an alternative route (eg, jejunostomy). A clear liquid diet can usually be initiated by postoperative day 1 or 2; most patients are able to advance to a regular diet over the next 48 to 72 hours. Early oral intake is a component of almost all pancreaticoduodenectomy enhanced recovery after surgery (ERAS) protocols [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
         A trial randomly assigned 114 patients to oral or enteral feeding after pancreaticoduodenectomy [
         <a href="#rid131">
          131
         </a>
         ]. Compared with enteral feeding, oral feeding did not increase the duration or grade of postoperative pancreatic fistulas and was associated with a shorter hospital stay and reduced costs.
        </p>
        <p>
         A systematic review found that normal oral intake was established more quickly compared with other enteral nutrition routes (eg, jejunostomy, gastrojejunostomy, or total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         ) and was associated with a shorter length of stay [
         <a href="#rid132">
          132
         </a>
         ]. However, patients with perioperative complications may require additional nutritional support. In the same systematic review, approximately 25 percent of patients fed orally required nutritional support, either because oral intake was insufficient or due to complications such as pancreatic fistula.
        </p>
        <p>
         General principles and practices of perioperative nutritional support are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">
          "Overview of perioperative nutrition support"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176956807">
         <span class="h2">
          Drain management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although whether prophylactic abdominal drainage reduces postoperative complications after pancreatic surgery is controversial, the use of surgical drains is a very common practice [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
         Any closed-suction drain placed during a pancreaticoduodenectomy should be managed according to the volume and character of the output. The normal peripancreatic drainage should be clear or straw colored. Green-tinged fluid suggests the presence of bile. If the fluid is cloudy or turbulent, a pancreatic leak should be suspected and a fluid amylase level should be obtained. A drain fluid amylase level that is more than three times higher than the upper limit of normal for the serum amylase level defines a pancreatic leak.
        </p>
        <p>
         If there is no evidence of a bile or pancreatic leak, the closed-suction drain placed at the time of surgery is usually removed once the patient is tolerating a regular diet. In one meta-analysis, a higher drain amylase concentration on the first day after major pancreatic resection was highly predictive of developing a pancreatic fistula and thereby requiring long-term drainage [
         <a href="#rid134">
          134
         </a>
         ]. Although there is some evidence that early drain removal may reduce intra‐abdominal infection rate, morbidity, and length of hospital stay for people with a low risk of postoperative pancreatic fistula [
         <a href="#rid133">
          133
         </a>
         ], most surgeons tailor drain care to the individual patient's progress, rather than arbitrary values of drain fluid amylase [
         <a href="#rid135">
          135,136
         </a>
         ].
        </p>
        <p>
         In our experience, most postoperative pancreatic and biliary fistulas close spontaneously, usually within four to six weeks after discharge [
         <a href="#rid137">
          137
         </a>
         ]. If a pancreatic or bile leak is present and the patient is ready for discharge, the drain should remain in place and can be removed in the outpatient setting once the fistula has resolved.
        </p>
        <p>
         Any T-tube placed to protect the hepaticojejunostomy can be removed in the office three to four weeks later. The T-tube can usually be removed without the need for a prior cholangiogram, provided that there is no evidence of a bile leak.
        </p>
        <p class="headingAnchor" id="H176956832">
         <span class="h2">
          Pancreatic enzyme supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients who have undergone pancreaticoduodenectomy will not need pancreatic enzyme supplementation. Although many patients will have several bowel movements a day for some weeks following discharge from the hospital as the gastrointestinal tract "readjusts" to the altered anatomy, bowel frequency almost always decreases, and most patients end up with two to three formed bowel movements daily.
        </p>
        <p>
         If steatorrhea is evident with oily floating stools, then pancreatic enzyme supplements should be prescribed with each meal (at least 30,000 units of lipase component/meal; one-half dose with snacks)  (
         <a class="graphic graphic_table graphicRef51385" href="/z/d/graphic/51385.html" rel="external">
          table 4
         </a>
         ). Antisecretory agents (histamine receptor antagonist, proton pump inhibitor) should also be given to decrease gastric acid secretion. It is almost never necessary to limit fat intake. If this approach does not provide relief, the patient should be referred to a gastroenterologist for further management. (See
         <a class="medical medical_review" href="/z/d/html/5647.html" rel="external">
          "Chronic pancreatitis: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176956909">
         <span class="h2">
          Prophylactic somatostatin analogues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Somatostatin or its analogues (eg,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         ,
         <a class="drug drug_general" data-topicid="87457" href="/z/d/drug information/87457.html" rel="external">
          pasireotide
         </a>
         , vapreotide), which reduce pancreatic, gastric, and enteric secretions, should theoretically be helpful for reducing postoperative pancreatic fistula, but studies evaluating this issue are conflicting [
         <a href="#rid138">
          138-146
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2579.html" rel="external">
          "Physiology of somatostatin and its analogues"
         </a>
         .)
        </p>
        <p>
         As a result, we do not recommend routine use of prophylactic somatostatin or any of its analogues (eg,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ) for patients undergoing resection of the head of the pancreas. Rather, somatostatin or its analogues may be used selectively to control the volume of output in patients who develop high-output pancreatic fistulas postoperatively.
        </p>
        <p>
         No significant differences in mortality have been identified in several systematic reviews whether or not somatostatin or its analogues are used [
         <a href="#rid139">
          139,140,142,147
         </a>
         ]. Somatostatin and its analogues may have an overall benefit in reducing morbidity following pancreatic operations, but the variable methods by which the agent is administered, outcomes reported, and definitions of complications, and particularly the definition of a pancreatic fistula, make it difficult to compare studies or clearly identify a subgroup for whom prophylactic treatment should be considered, and the optimal means by which it should be administered [
         <a href="#rid148">
          148
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2013 Cochrane systematic review and meta-analysis that included 21 trials evaluating somatostatin and its analogues (predominantly
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ; two studies
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         ) following a pancreatic surgery (variety of indications and types of surgery) found a decreased incidence of pancreas-specific complications in those patients who received prophylactic somatostatin analogues postoperatively [
         <a href="#rid147">
          147
         </a>
         ]. The incidence of pancreatic fistula was reduced among those who received somatostatin analogues compared with controls (relative risk [RR] 0.66, 95% CI 0.55-0.79); however, there were no significant differences in the rate of pancreatic fistula among the four trials that clearly distinguished clinically significant fistula. A significant decrease in the incidence of sepsis (RR 0.42, 95% CI 0.21-0.85), risk for any complication, and number of complications was seen in the somatostatin analogue group (RR 0.70, 95% CI 0.61-0.80; RR 0.70, 95% CI 0.60-0.82). No significant differences were identified for rates of reoperation, anastomotic leak, postoperative pancreatitis, renal failure, bleeding, abdominal collections, delayed gastric emptying, or length of hospital stay.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 meta-analysis of eight randomized trials did
         <strong>
          not
         </strong>
         find that prophylactic
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         significantly reduced the total number of postoperative pancreatic fistulas, the number of clinically significant fistulas, the length of hospital stay, or postoperative mortality [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, a single-center trial evaluating
         <a class="drug drug_general" data-topicid="87457" href="/z/d/drug information/87457.html" rel="external">
          pasireotide
         </a>
         , which has a longer half-life than
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         and a different binding profile, found that 14 doses of pasireotide administered during the first seven postoperative days reduced the risk of clinically significant pancreatic fistulas, leak, or abscess compared with placebo (9.2 versus 20.9 percent) [
         <a href="#rid138">
          138
         </a>
         ], without increasing cost [
         <a href="#rid150">
          150
         </a>
         ]. These reductions remained significant in the subgroups of patients who underwent pancreaticoduodenectomy (10 versus 21 percent), distal pancreatectomy (7 versus 23 percent), and who had dilated (2 versus 15 percent) or nondilated pancreatic duct (15 versus 27 percent). Another single-center nonrandomized study also found that the routine use of pasireotide reduced the incidence of clinically relevant pancreatic fistula/abscess (13 versus 21 percent) and biliary leakage (0.6 versus 3.4 percent), compared with historical controls [
         <a href="#rid151">
          151
         </a>
         ]. These results, however, have not been reproduced by others [
         <a href="#rid152">
          152
         </a>
         ]. Therefore, results from more multicenter randomized trials are needed before wider, routine use of pasireotide can be recommended.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2258323345">
         <span class="h2">
          Readmission prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to a review of the Surveillance, Epidemiology, and End Results (SEER) database, nearly one-fourth of patients in the United States are readmitted to the hospital following pancreaticoduodenectomy [
         <a href="#rid153">
          153
         </a>
         ]. Preoperative patient comorbidities, as opposed to provider- or hospital-specific variables, appear to be more important for predicting who will require readmission.
        </p>
        <p>
         We advocate close surgeon-patient communication in the immediate postoperative period to avoid unnecessary readmissions. For those who undergo surgery at a tertiary referral center away from home, participation from a local surgeon or other clinicians familiar with the patient and with whom the operating surgeon can communicate can be very helpful.
        </p>
        <p class="headingAnchor" id="H176949700">
         <span class="h1">
          PERIOPERATIVE MORBIDITY AND MORTALITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In experienced high-volume centers, pancreaticoduodenectomy can be performed with a low postoperative mortality of &lt;4 percent and morbidity of 40 to 50 percent. The five-year survival for completely resected patients is 20 to 30 percent. (See
         <a class="medical medical_review" href="/z/d/html/2482.html" rel="external">
          "Overview of surgery in the treatment of exocrine pancreatic cancer and prognosis", section on 'Outcomes of pancreaticoduodenectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1033613487">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although previously associated with high morbidity and mortality rates, modern series show that in experienced hands, the conventional Whipple procedure is associated with a perioperative mortality rate of less than 4 percent, and 20 to 30 percent five-year survival in completely resected patients [
         <a href="#rid154">
          154-160
         </a>
         ]. This relatively low perioperative mortality rate represents a decline from over 15 percent in the 1970s, making the pancreaticoduodenectomy a more attractive option.
        </p>
        <p>
         One of the most important reasons for this is the greater experience of a limited number of surgeons who perform the procedure regularly in high-volume institutions [
         <a href="#rid161">
          161-164
         </a>
         ]. The relationship between surgeon and hospital volume and postoperative mortality and survival after pancreatic cancer surgery has been evaluated by several meta-analyses [
         <a href="#rid165">
          165,166
         </a>
         ]. In one meta-analysis that included 14 studies, there was a significant association between hospital volume and postoperative mortality (odds ratio [OR] 0.32, 95% CI 0.16-0.64), as well as overall survival (hazard ratio for death 0.79, 95% CI 0.70-0.89) [
         <a href="#rid165">
          165
         </a>
         ]. However, morbidity rates remain high (40 to 50 percent).
        </p>
        <p>
         In a French study of 3195 patients undergoing pancreatic resection at high-volume centers, 4.4 percent died within 90 days of surgery [
         <a href="#rid167">
          167
         </a>
         ]. The cause of death was determined in 90 percent of deaths, of which 30 percent were preventable. Young age and arterial resection (especially unplanned) were often associated with avoidable mortality.
        </p>
        <p>
         Previous observational studies have shown that mortality after pancreatic resection is related to failure to rescue rather than to complications [
         <a href="#rid168">
          168
         </a>
         ]. As such, early recognition and minimally invasive management of postoperative complications may reduce mortality rates [
         <a href="#rid169">
          169
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H176949706">
         <span class="h2">
          Delayed gastric emptying
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vomiting after oral intake is resumed can be a manifestation of delayed gastric emptying. The mean incidence of delayed gastric emptying is 17 percent, although the range varies widely among trials [
         <a href="#rid170">
          170
         </a>
         ]. Possible risk factors for delayed gastric emptying include prior abdominal surgery, history of cholangitis, and diabetes mellitus [
         <a href="#rid171">
          171-173
         </a>
         ]. It is important to not overlook the possibility of pancreatic fistula with an intra-abdominal fluid collection as a cause of delayed gastric emptying. Thus, an abdominal computed tomography (CT) scan should be done if vomiting occurs.
        </p>
        <p>
         The incidence of delayed gastric emptying does not appear to differ following conventional versus pylorus-preserving pancreaticoduodenectomy [
         <a href="#rid62">
          62
         </a>
         ] or single loop versus Roux-en-Y gastrointestinal reconstruction. (See
         <a class="local">
          'Pylorus-preserving pancreaticoduodenectomy'
         </a>
         above and
         <a class="local">
          'Gastrointestinal anastomosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H176949718">
         <span class="h2">
          Pancreatic fistula
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postoperative pancreatic fistula (POPF) is diagnosed when the amylase content of any measurable volume of fluid from the pancreatic drain on or after postoperative day 3 is greater than three times the upper limit of the normal serum amylase content, based on standards from the International Study Group on Pancreatic Fistulas (ISGPF) [
         <a href="#rid174">
          174,175
         </a>
         ]. Clinically relevant postoperative pancreatic fistulas (grade B or C [
         <a href="#rid176">
          176
         </a>
         ]) occur in approximately 5 to 10 percent of patients, although in some series the incidence is as high as 22 percent [
         <a href="#rid177">
          177,178
         </a>
         ]. Pancreatic fistulas can lead to sepsis and hemorrhage if they are not adequately drained externally. These complications are associated with mortality of 20 to 40 percent, prolonged hospitalization, and increased hospital expenses [
         <a href="#rid177">
          177
         </a>
         ].
        </p>
        <p>
         The risk of developing POPF is increased with various factors, such as high body mass index (BMI), preoperative comorbidities such as jaundice, as well as a soft pancreas and a narrow pancreatic duct. Other factors that have been associated with an increased risk of POPF include drain amylase &gt;4000 U/L on postoperative day 1, increased intraoperative blood loss, and prolonged operative time [
         <a href="#rid177">
          177,179-181
         </a>
         ]. In one study, a risk score calculated using only BMI and pancreatic duct width on preoperative CT imaging, accurately predicted the risk of POPF [
         <a href="#rid182">
          182
         </a>
         ].
        </p>
        <p>
         In a study of 2752 patients under pancreatic resection, 256 patients (9.3 percent) developed a clinically relevant POPF (ISGPF grade B or C) [
         <a href="#rid183">
          183
         </a>
         ]. Detection of microorganisms in the POPF was associated with a higher rate of post-pancreatectomy hemorrhage (42 versus 22 percent), sepsis (38 versus 7 percent), wound infection (30 versus 7 percent), reoperation (48 versus 11 percent), overall 90 day mortality (20 versus 4 percent), and length of hospital stay (median 42 versus 26 days). An infected POPF was identified as an independent risk factor for sepsis, wound infection, and reoperation by multivariate analysis. However, it is unclear how this increased risk for complications can be best mitigated (eg, by earlier antibiotic therapy, or by procedural or surgical intervention).
        </p>
        <p>
         In the past decade, neoadjuvant therapy has been used more often for patients with borderline and locally advanced pancreatic cancer. In such patients, the risk factors, incidences, and implications of POPF after pancreaticoduodenectomy may be different. In a single-center retrospective study of 753 patients, the rate of clinically relevant POPF (CR-POPF) was 3.6-fold lower in patients receiving neoadjuvant therapy versus upfront resection (3.8 versus 13.8 percent) [
         <a href="#rid184">
          184
         </a>
         ]. However, overall survival was worse for patients who develop CR-POPF after neoadjuvant therapy (17 months with CR-POPF versus 34 months without CR-POPF). In multivariate analysis, CR-POPF following neoadjuvant therapy was not associated with the usual risk factors except one, soft pancreatic texture. The authors of this study suggested that neoadjuvant therapy altered the normal pancreatic parenchyma as much as the diseased portion to make it more fibrotic and resistant to POPF but that a persistently soft parenchyma following neoadjuvant therapy portends poor response to neoadjuvant therapy, hence the worse survival.
        </p>
        <p class="headingAnchor" id="H101604580">
         <span class="h3">
          Prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of postoperative pancreatic fistula using various techniques for handling the pancreatic stump or anastomosis, prophylactic somatostatin and its analogues, and prophylactic pancreatic duct stenting has been attempted with varying success. In a 2022 meta-analysis of 12 interventions, external pancreatic duct drainage was the only intervention associated with reduced rates of both CR-POPF (OR 0.40, 95% CI 0.20-0.80) and all POPF (OR 0.42, 95% CI 0.25-0.70) [
         <a href="#rid185">
          185
         </a>
         ]. Ulinastatin was associated with reduced rates of CR-POPF (OR 0.24, 95% CI 0.06-0.93). Invagination (versus duct-to-mucosa) pancreatojejunostomy was associated with reduced rates of all-POPF (OR 0.60, 95% CI 0.40-0.90).
        </p>
        <p>
         Specific methods are discussed above for resection of the pancreatic head and discussed separately for resection of the tail of the pancreas. (See
         <a class="local">
          'Pancreaticoduodenectomy'
         </a>
         above and
         <a class="local">
          'Adjuncts'
         </a>
         above and
         <a class="local">
          'Prophylactic somatostatin analogues'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5660.html" rel="external">
          "Surgical resection of lesions of the body and tail of the pancreas", section on 'Central pancreatectomy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5660.html" rel="external">
          "Surgical resection of lesions of the body and tail of the pancreas", section on 'Postoperative care and follow-up'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H900327478">
         <span class="h2">
          Bile leak
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bile leaks from the choledochal-jejunal anastomosis occur in 1 to 3 percent of cases and are heralded by the appearance of bile in the drainage fluid [
         <a href="#rid186">
          186
         </a>
         ]. If this occurs, the drain should be left in place until the leak stops. If it is still present when the patient is ready for discharge, the patient can go home with the drain in place and have the drain removed in the office after the leak stops. (See
         <a class="local">
          'Drain management'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3737562495">
         <span class="h2">
          New-onset diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancreaticoduodenectomy may lead to new-onset diabetes mellitus. The incidence is best estimated by a systematic review and meta-analysis of 22 studies [
         <a href="#rid187">
          187
         </a>
         ]. The mean weighted overall proportion of new-onset diabetes mellitus after pancreaticoduodenectomy was 16 percent (95% CI 12 to 20 percent); 6 percent developed insulin-dependent new-onset diabetes (95% CI 4 to 10 percent). The risk is the same regardless of whether the indication for the surgery is benign or malignant.
        </p>
        <p>
         In another study of 50 patients with a median follow-up of 32 months, the incidence of new-onset impaired glucose tolerance/diabetes mellitus was 22 percent after pancreaticoduodenectomy, and a percentage of pancreatic remnant volume &lt;48.8 percent was an independent factor associated with new-onset diabetes [
         <a href="#rid188">
          188
         </a>
         ].
        </p>
        <p>
         In another study of 403 patients followed for at least 10 years, approximately 16.6 percent developed diabetes following pancreaticoduodenectomy [
         <a href="#rid189">
          189
         </a>
         ]. A preoperative HbA1c &gt;5.4 percent predicted new-onset diabetes with a relative risk of 2.944.
        </p>
        <p class="headingAnchor" id="H122051474">
         <span class="h2">
          Pancreaticojejunal anastomotic stricture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancreaticojejunal anastomotic (PJA) stricture is a rare late complication that occurs at a median of 34 months after pancreaticoduodenectomy but only in 1.4 to 11.4 percent of patients, according to a systematic review [
         <a href="#rid190">
          190
         </a>
         ]. Most present with symptoms of postprandial abdominal pain, recurrent acute pancreatitis, and impaired pancreatic function. Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP) is the best modality to confirm the diagnosis. Only symptomatic patients require treatment, which consists of endoscopic dilation (with ultrasound-assisted "rendezvous" techniques), surgical repair, or total pancreatectomy with islet auto-transplantation (last resort).
        </p>
        <p class="headingAnchor" id="H4089861479">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111947.html" rel="external">
          "Society guideline links: Pancreatic cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176949724">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/854.html" rel="external">
          "Patient education: Pancreatic cancer (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2001.html" rel="external">
          "Patient education: Chronic pancreatitis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H176949730">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for pancreatic head resection
         </strong>
         – The most common indication for pancreaticoduodenectomy is the presence of a malignant or premalignant neoplasm in the head of the pancreas or another periampullary structure (bile duct, ampulla, or duodenum). Other potential indications include pancreatic or duodenal trauma and chronic pancreatitis. (See
         <a class="local">
          'Indications for pancreatic head resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative biliary stenting
         </strong>
         – For patients presenting with obstructive jaundice, we suggest against routine preoperative biliary decompression (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, we perform preoperative biliary stenting in these following clinical scenarios (see
         <a class="local">
          'Preoperative biliary drainage'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The serum bilirubin concentration exceeds 20 mg/dL.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surgery will be delayed for longer than two weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is intractable cholangitis or pruritus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When preoperative biliary stenting is elected, we prefer to use a plastic biliary stent (≥10 French), keeping the proximal end of the stent at or below the level of the cystic duct takeoff.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative imaging
         </strong>
         – Preoperative imaging with high-resolution computed tomographic (CT) scan with 1 to 2 mm cuts through the pancreas during the early arterial and venous phase (pancreatic protocol) provides the best assessment of resectability and the peripancreatic vasculature (eg, anatomic anomaly, mesenteric stenosis, need for portal or superior mesenteric vein excision). (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Staging laparoscopy
         </strong>
         –
         <strong>
         </strong>
         For patients with a high likelihood of unresectability that has not been confirmed preoperatively, staging laparoscopy permits examination of the liver and peritoneal surfaces as well as biopsy of any suspicious areas. If metastatic tumor is found, laparotomy may be avoided. If the patient is found to have unresectable disease during the course of staging laparoscopy or an attempted pancreaticoduodenectomy and downstaging neoadjuvant therapy is not an option (eg, liver or peritoneal metastases, very extensive local disease with complete major vascular occlusion, etc), surgical biliary and gastric bypass may be performed, or alternatively, the patient may undergo endoscopic biliary stenting. (See
         <a class="local">
          'Staging laparoscopy'
         </a>
         above and
         <a class="local">
          'Palliative surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vascular resection
         </strong>
         – Pancreaticoduodenectomy with portal or superior mesenteric vein resection and reconstruction is considered a standard approach for pancreatic adenocarcinomas that focally involve one of the veins, provided that adequate inflow and outflow veins are present, the tumor does not involve the superior mesenteric artery or hepatic artery, and an R0 resection can be accomplished. (See
         <a class="local">
          'Vascular evaluation'
         </a>
         above and
         <a class="local">
          'Vein excision and reconstruction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pancreaticoduodenectomy
         </strong>
         – For most patients, we suggest a pylorus-preserving pancreaticoduodenectomy rather than the conventional pancreaticoduodenectomy (ie, Whipple procedure) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The advantages of a pylorus-preserving pancreaticoduodenectomy include the potential time savings and lower rate of blood loss, with similar oncologic outcomes. However, a conventional pancreaticoduodenectomy (Whipple) operation should be performed if the tumor involves the proximal duodenum, pylorus, or gastric antrum. (See
         <a class="local">
          'Conventional versus modified pancreaticoduodenectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal reconstruction
         </strong>
         – Following resection, gastrointestinal reconstruction provides a drainage route for the remaining pancreas, the bile duct, and the stomach. There are multiple accepted methods of gastrointestinal reconstruction; the choice is by surgeon preference as one method has not been shown to be consistently superior to others (see
         <a class="local">
          'Gastrointestinal reconstruction'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The pancreatic-enteric anastomosis can be either a pancreaticojejunostomy  (
         <a class="graphic graphic_figure graphicRef120316 graphicRef96650" href="/z/d/graphic/120316.html" rel="external">
          figure 3A-B
         </a>
         ) or a pancreaticogastrostomy  (
         <a class="graphic graphic_figure graphicRef101029" href="/z/d/graphic/101029.html" rel="external">
          figure 5
         </a>
         ). (See
         <a class="local">
          'Pancreaticojejunostomy versus pancreaticogastrostomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A pancreaticojejunostomy can be constructed by an end-to-side duct-to-mucosa anastomosis  (
         <a class="graphic graphic_figure graphicRef53080" href="/z/d/graphic/53080.html" rel="external">
          figure 6
         </a>
         ) or invagination of the pancreatic remnant. The invagination method can be performed either end-to-side or end-to-end  (
         <a class="graphic graphic_figure graphicRef106226" href="/z/d/graphic/106226.html" rel="external">
          figure 7
         </a>
         ). (See
         <a class="local">
          'Duct-to-mucosa versus invagination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The biliary-enteric anastomosis is performed as a hepaticojejunostomy to the same loop of jejunum used to drain the pancreas. (See
         <a class="local">
          'Biliary-enteric anastomosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The stomach or duodenum (pylorus sparing) can be drained into the same proximal jejunal loop brought up to the right upper quadrant for the pancreatic and biliary anastomosis  (
         <a class="graphic graphic_figure graphicRef120316" href="/z/d/graphic/120316.html" rel="external">
          figure 3A
         </a>
         ) or to a separate Roux limb of more distal jejunum  (
         <a class="graphic graphic_figure graphicRef96650" href="/z/d/graphic/96650.html" rel="external">
          figure 3B
         </a>
         ). The reconstruction can be placed anterior (antecolic) or posterior (retrocolic) to the transverse colon. (See
         <a class="local">
          'Gastrointestinal anastomosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimally invasive approaches
         </strong>
         – In some studies, minimally invasive (laparoscopic or robotic) pancreaticoduodenectomy can be accomplished with less blood loss and shorter length of hospital stay, albeit longer operative time, compared with open surgery. However, it is highly complex and therefore should only be performed in selected patients in high-volume centers. (See
         <a class="local">
          'Open versus minimally invasive'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enucleation
         </strong>
         – Some small (ie, ≤1 cm) benign lesions in the head of the pancreas can be enucleated. Compared with pancreaticoduodenectomy, enucleation is more likely to cause a pancreatic fistula rate but less likely to lead to postoperative pancreatic insufficiency. Enucleation should not be used when the lesion is large (usually &gt;2 cm) or when there is a chance that the lesion may be malignant. Enucleation is most commonly performed for pancreatic neuroendocrine tumors, especially insulinomas. (See
         <a class="local">
          'Enucleation procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drain management
         </strong>
         – Following pancreatic resection, we suggest placing drains selectively in patients who are at a high risk of developing pancreatic fistula (eg, those with a soft and friable pancreas, those with a small [&lt;2 mm] pancreatic duct), rather than routinely (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Any drain placed at the time of surgery is usually removed once the patient is tolerating a regular diet, provided there is no evidence of bile or pancreatic leak. If a leak is present, the patient may be discharged home with the drain in place. Most postoperative pancreatic and biliary fistulas close spontaneously, usually within four to six weeks after discharge, after which the drains can be removed in the office. (See
         <a class="local">
          'Drainage of the pancreatic bed'
         </a>
         above and
         <a class="local">
          'Drain management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Somatostatin analogues
         </strong>
         – We suggest against routine use of prophylactic somatostatin or any of its analogues (eg,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ) for patients undergoing resection of the head of the pancreas (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We limit the use of these medications to control the volume of output in patients who develop high-output pancreatic fistulas postoperatively. (See
         <a class="local">
          'Prophylactic somatostatin analogues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morbidity and mortality
         </strong>
         – At experienced, high-volume centers, pancreaticoduodenectomy can be performed with a low postoperative mortality of &lt;4 percent and morbidity of 40 to 50 percent. Common complications include delayed gastric emptying (17 percent), pancreatic fistula (5 to 10 percent clinically relevant), and bile leak (1 to 3 percent). The lowest operative mortality rates and best long-term cancer outcomes have been demonstrated at high-volume centers. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Perioperative morbidity and mortality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2202967325">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Mark Girgis, MD, and Jonathan King, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg 2007; 245:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong Y, Gonen M, Rubin D, et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005; 242:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 2003; 138:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryder NM, Ko CY, Hines OJ, et al. Primary duodenal adenocarcinoma: a 40-year experience. Arch Surg 2000; 135:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashley SW, Reber HA. The Whipple operation: The classical surgical procedure to treat chronic pancreatitis. Digestive Surgery 1996; 13:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf AM, Pucci MJ, Gabale SD, et al. Safety of perioperative aspirin therapy in pancreatic operations. Surgery 2014; 155:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga M, Ljungqvist O, Soeters P, et al. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr 2009; 28:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RC, Pooley M, George CR, Faithful GR. Preoperative percutaneous transhepatic internal drainage in obstructive jaundice: a randomized, controlled trial examining renal function. Surgery 1985; 97:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pitt HA, Gomes AS, Lois JF, et al. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985; 201:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai EC, Mok FP, Fan ST, et al. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994; 81:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McPherson GA, Benjamin IS, Hodgson HJ, et al. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg 1984; 71:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatfield AR, Tobias R, Terblanche J, et al. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 1982; 2:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eshuis WJ, van der Gaag NA, Rauws EA, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg 2010; 252:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mumtaz K, Hamid S, Jafri W. Endoscopic retrograde cholangiopancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgery. Cochrane Database Syst Rev 2007; :CD006001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang Y, Gurusamy KS, Wang Q, et al. Pre-operative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev 2012; :CD005444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang Y, Gurusamy KS, Wang Q, et al. Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice. Br J Surg 2013; 100:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheufele F, Schorn S, Demir IE, et al. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. Surgery 2017; 161:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singal AK, Ross WA, Guturu P, et al. Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. Dig Dis Sci 2011; 56:3678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gloor B, Todd KE, Reber HA. Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach. Cancer 1997; 79:1780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg WM, Barkin J, Bradley EL 3rd, et al. Workup of a patient with a mass in the head of the pancreas. Pancreas 1998; 17:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taoka H, Hauptmann E, Traverso LW, et al. How accurate is helical computed tomography for clinical staging of pancreatic cancer? Am J Surg 1999; 177:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997; 168:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vedantham S, Lu DS, Reber HA, Kadell B. Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. AJR Am J Roentgenol 1998; 170:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 117:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soloff EV, Al-Hawary MM, Desser TS, et al. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 2022; 218:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shukla PJ, Barreto SG, Kulkarni A, et al. Vascular anomalies encountered during pancreatoduodenectomy: do they influence outcomes? Ann Surg Oncol 2010; 17:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaujoux S, Sauvanet A, Vullierme MP, et al. Ischemic complications after pancreaticoduodenectomy: incidence, prevention, and management. Ann Surg 2009; 249:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diepenhorst GM, van Ruler O, Besselink MG, et al. Influence of prophylactic probiotics and selective decontamination on bacterial translocation in patients undergoing pancreatic surgery: a randomized controlled trial. Shock 2011; 35:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angelica MI, Ellis RJ, Liu JB, et al. Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. JAMA 2023; 329:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sudo T, Murakami Y, Uemura K, et al. Specific antibiotic prophylaxis based on bile cultures is required to prevent postoperative infectious complications in pancreatoduodenectomy patients who have undergone preoperative biliary drainage. World J Surg 2007; 31:2230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondo K, Chijiiwa K, Ohuchida J, et al. Selection of prophylactic antibiotics according to the microorganisms isolated from surgical site infections (SSIs) in a previous series of surgeries reduces SSI incidence after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 2013; 20:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammed S, Evans C, VanBuren G, et al. Treatment of bacteriobilia decreases wound infection rates after pancreaticoduodenectomy. HPB (Oxford) 2014; 16:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham H, Chen A, Nahm CB, et al. The Role of Targeted Versus Standard Antibiotic Prophylaxis in Pancreatoduodenectomy in Reducing Postoperative Infectious Complications: A Systematic Review and Meta-analysis. Ann Surg 2022; 275:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagarasanu A, Alotaibi GS, Hrimiuc R, et al. Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2016; 23:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinke CE, Drebin JA, Kreider S, et al. Timing of preoperative pharmacoprophylaxis for pancreatic surgery patients: a venous thromboembolism reduction initiative. Ann Surg Oncol 2012; 19:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gemenetzis G, Groot VP, Blair AB, et al. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. J Surg Oncol 2018; 118:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazanjian KK, Reber HA, Hines OJ. Laparoscopic gastrojejunostomy for gastric outlet obstruction in pancreatic cancer. Am Surg 2004; 70:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 2007; 142:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staerkle RF, Vuille-Dit-Bille RN, Soll C, et al. Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. Cochrane Database Syst Rev 2021; 1:CD011490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DB, Farnell MB, Lillemoe KD, et al. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machairas N, Raptis DA, Velázquez PS, et al. The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. Ann Surg 2021; 274:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleive D, Sahakyan MA, Berstad AE, et al. Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. Br J Surg 2017; 104:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Demir IE, Schorn S, et al. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. Transl Gastroenterol Hepatol 2019; 4:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinny-Köster B, van Oosten F, Habib JR, et al. Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Surgery 2020; 168:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruns H, Rahbari NN, Löffler T, et al. Perioperative management in distal pancreatectomy: results of a survey in 23 European participating centres of the DISPACT trial and a review of literature. Trials 2009; 10:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaminsky PM, Mezhir JJ. Intraperitoneal drainage after pancreatic resection: a review of the evidence. J Surg Res 2013; 184:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrowsky H, Demartines N, Rousson V, Clavien PA. Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses. Ann Surg 2004; 240:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng Y, Xia J, Lai M, et al. Prophylactic abdominal drainage for pancreatic surgery. Cochrane Database Syst Rev 2016; 10:CD010583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heslin MJ, Harrison LE, Brooks AD, et al. Is intra-abdominal drainage necessary after pancreaticoduodenectomy? J Gastrointest Surg 1998; 2:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher WE, Hodges SE, Silberfein EJ, et al. Pancreatic resection without routine intraperitoneal drainage. HPB (Oxford) 2011; 13:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa-Gallego C, Brennan MF, Dʼangelica M, et al. Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg 2013; 258:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta VV, Fisher SB, Maithel SK, et al. Is it time to abandon routine operative drain use? A single institution assessment of 709 consecutive pancreaticoduodenectomies. J Am Coll Surg 2013; 216:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conlon KC, Labow D, Leung D, et al. Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection. Ann Surg 2001; 234:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witzigmann H, Diener MK, Kienkötter S, et al. No Need for Routine Drainage After Pancreatic Head Resection: The Dual-Center, Randomized, Controlled PANDRA Trial (ISRCTN04937707). Ann Surg 2016; 264:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Buren G 2nd, Bloomston M, Hughes SJ, et al. A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg 2014; 259:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang W, He S, Cheng Y, et al. Prophylactic abdominal drainage for pancreatic surgery. Cochrane Database Syst Rev 2018; 6:CD010583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hüttner FJ, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2016; 2:CD006053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diener MK, Knaebel HP, Heukaufer C, et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg 2007; 245:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel AG, Toyama MT, Kusske AM, et al. Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better? Arch Surg 1995; 130:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seiler CA, Wagner M, Bachmann T, et al. Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005; 92:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin PW, Shan YS, Lin YJ, Hung CJ. Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure. Hepatogastroenterology 2005; 52:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenger FA, Jacobi CA, Haubold K, et al. [Gastrointestinal quality of life after duodenopancreatectomy in pancreatic carcinoma. Preliminary results of a prospective randomized study: pancreatoduodenectomy or pylorus-preserving pancreatoduodenectomy]. Chirurg 1999; 70:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004; 240:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloechle C, Broering DC, Latuske C, et al. Prospective randomized study to evaluate quality of life after partial pancreatoduodenectomy according to Whipple versus pylorus preserving pancreatoduodenectomy according to Longmire-Traverso for periampullary carcinoma. Dtsch Gesellschaft Chir 1999; Suppl-1:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paquet KJ . Vergleich der partiellen Duodenopankreatektomie (Whipple operation) mit der pylorouserhaltenden Zephaloduodenopankreatektomie: eine prospektive kontrollierte, randomisierte Langzeitstudie. Chir Gastroenterol 1998; 14:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hackert T, Probst P, Knebel P, et al. Pylorus Resection Does Not Reduce Delayed Gastric Emptying After Partial Pancreatoduodenectomy: A Blinded Randomized Controlled Trial (PROPP Study, DRKS00004191). Ann Surg 2018; 267:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klaiber U, Probst P, Hüttner FJ, et al. Randomized Trial of Pylorus-Preserving vs. Pylorus-Resecting Pancreatoduodenectomy: Long-Term Morbidity and Quality of Life. J Gastrointest Surg 2020; 24:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williamson RC, Bliouras N, Cooper MJ, Davies ER. Gastric emptying and enterogastric reflux after conservative and conventional pancreatoduodenectomy. Surgery 1993; 114:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klinkenbijl JH, van der Schelling GP, Hop WC, et al. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 1992; 216:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLeod RS, Taylor BR, O'Connor BI, et al. Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. Am J Surg 1995; 169:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warshaw AL, Torchiana DL. Delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy. Surg Gynecol Obstet 1985; 160:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii T, Kanda M, Kodera Y, et al. Preservation of the pyloric ring has little value in surgery for pancreatic head cancer: a comparative study comparing three surgical procedures. Ann Surg Oncol 2012; 19:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumoto I, Shinzeki M, Asari S, et al. A prospective randomized comparison between pylorus- and subtotal stomach-preserving pancreatoduodenectomy on postoperative delayed gastric emptying occurrence and long-term nutritional status. J Surg Oncol 2014; 109:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassi C, Falconi M, Molinari E, et al. Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study. Ann Surg 2005; 242:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995; 222:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellner UF, Sick O, Olschewski M, et al. Randomized controlled single-center trial comparing pancreatogastrostomy versus pancreaticojejunostomy after partial pancreatoduodenectomy. J Gastrointest Surg 2012; 16:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffas JP, Suc B, Msika S, et al. A controlled randomized multicenter trial of pancreatogastrostomy or pancreatojejunostomy after pancreatoduodenectomy. Am J Surg 2005; 189:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rault A, SaCunha A, Klopfenstein D, et al. Pancreaticojejunal anastomosis is preferable to pancreaticogastrostomy after pancreaticoduodenectomy for longterm outcomes of pancreatic exocrine function. J Am Coll Surg 2005; 201:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keck T, Wellner UF, Bahra M, et al. Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial. Ann Surg 2016; 263:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topal B, Fieuws S, Aerts R, et al. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. Lancet Oncol 2013; 14:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takano S, Ito Y, Watanabe Y, et al. Pancreaticojejunostomy versus pancreaticogastrostomy in reconstruction following pancreaticoduodenectomy. Br J Surg 2000; 87:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menahem B, Guittet L, Mulliri A, et al. Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Ann Surg 2015; 261:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng Y, Briarava M, Lai M, et al. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy. Cochrane Database Syst Rev 2017; 9:CD012257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne RF, Pain JA. Duct-to-mucosa pancreaticogastrostomy is a safe anastomosis following pancreaticoduodenectomy. Br J Surg 2006; 93:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy EP, Yeo CJ. Dunking pancreaticojejunostomy versus duct-to-mucosa anastomosis. J Hepatobiliary Pancreat Sci 2011; 18:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcus SG, Cohen H, Ranson JH. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg 1995; 221:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilambi R, Singh AN. Duct-to-mucosa versus dunking techniques of pancreaticojejunostomy after pancreaticoduodenectomy: Do we need more trials? A systematic review and meta-analysis with trial sequential analysis. J Surg Oncol 2018; 117:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hai H, Li Z, Zhang Z, et al. Duct-to-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy. Cochrane Database Syst Rev 2022; 3:CD013462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winter JM, Cameron JL, Campbell KA, et al. Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg 2006; 10:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon RT, Fan ST, Lo CM, et al. External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann Surg 2007; 246:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motoi F, Egawa S, Rikiyama T, et al. Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after pancreaticojejunostomy. Br J Surg 2012; 99:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pessaux P, Sauvanet A, Mariette C, et al. External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial. Ann Surg 2011; 253:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong Z, Xu J, Wang Z, Petrov MS. Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy. Cochrane Database Syst Rev 2016; :CD008914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuroki T, Tajima Y, Kitasato A, et al. Stenting versus non-stenting in pancreaticojejunostomy: a prospective study limited to a normal pancreas without fibrosis sorted by using dynamic MRI. Pancreas 2011; 40:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suc B, Msika S, Fingerhut A, et al. Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection: prospective randomized trial. Ann Surg 2003; 237:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lillemoe KD, Cameron JL, Kim MP, et al. Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg 2004; 8:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng Y, He S, Cheng Y, et al. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. Cochrane Database Syst Rev 2020; 3:CD009621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ke S, Ding XM, Gao J, et al. A prospective, randomized trial of Roux-en-Y reconstruction with isolated pancreatic drainage versus conventional loop reconstruction after pancreaticoduodenectomy. Surgery 2013; 153:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busquets J, Martín S, Fabregat J, et al. Randomized trial of two types of gastrojejunostomy after pancreatoduodenectomy and risk of delayed gastric emptying (PAUDA trial). Br J Surg 2019; 106:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strasberg SM, Drebin JA, Soper NJ. Evolution and current status of the Whipple procedure: an update for gastroenterologists. Gastroenterology 1997; 113:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsalis K, Antoniou N, Koukouritaki Z, et al. Successful treatment of recurrent cholangitis by constructing a hepaticojejunostomy with long Roux-en-Y limb in a long-term surviving patient after a Whipple procedure for pancreatic adenocarcinoma. Am J Case Rep 2014; 15:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiliotis J, Karnabatidis D, Vaxevanidou A, et al. Acute cholangitis due to afferent loop syndrome after a Whipple procedure: a case report. Cases J 2009; 2:6339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gangavatiker R, Pal S, Javed A, et al. Effect of antecolic or retrocolic reconstruction of the gastro/duodenojejunostomy on delayed gastric emptying after pancreaticoduodenectomy: a randomized controlled trial. J Gastrointest Surg 2011; 15:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tani M, Terasawa H, Kawai M, et al. Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial. Ann Surg 2006; 243:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chijiiwa K, Imamura N, Ohuchida J, et al. Prospective randomized controlled study of gastric emptying assessed by (13)C-acetate breath test after pylorus-preserving pancreaticoduodenectomy: comparison between antecolic and vertical retrocolic duodenojejunostomy. J Hepatobiliary Pancreat Surg 2009; 16:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eshuis WJ, van Eijck CH, Gerhards MF, et al. Antecolic versus retrocolic route of the gastroenteric anastomosis after pancreatoduodenectomy: a randomized controlled trial. Ann Surg 2014; 259:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamandl D, Sahora K, Prucker J, et al. Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study. World J Surg 2014; 38:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hüttner FJ, Klotz R, Ulrich A, et al. Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy. Cochrane Database Syst Rev 2022; 1:CD011862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Wu WM, You L, Zhao YP. Robotic versus open pancreatectomy: a systematic review and meta-analysis. Ann Surg Oncol 2013; 20:1774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Rooij T, Lu MZ, Steen MW, et al. Minimally Invasive Versus Open Pancreatoduodenectomy: Systematic Review and Meta-analysis of Comparative Cohort and Registry Studies. Ann Surg 2016; 264:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang S, Shi N, You L, et al. Minimally invasive surgical approach versus open procedure for pancreaticoduodenectomy: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96:e8619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen K, Pan Y, Liu XL, et al. Minimally invasive pancreaticoduodenectomy for periampullary disease: a comprehensive review of literature and meta-analysis of outcomes compared with open surgery. BMC Gastroenterol 2017; 17:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palanivelu C, Senthilnathan P, Sabnis SC, et al. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. Br J Surg 2017; 104:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poves I, Burdío F, Morató O, et al. Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy: The PADULAP Randomized Controlled Trial. Ann Surg 2018; 268:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hilst J, de Rooij T, Bosscha K, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol 2019; 4:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croome KP, Farnell MB, Que FG, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg 2014; 260:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zenoni SA, Arnoletti JP, de la Fuente SG. Recent developments in surgery: minimally invasive approaches for patients requiring pancreaticoduodenectomy. JAMA Surg 2013; 148:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boone BA, Zenati M, Hogg ME, et al. Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve. JAMA Surg 2015; 150:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SE, Shyr BU, Chen SC, Shyr YM. Comparison between robotic and open pancreaticoduodenectomy with modified Blumgart pancreaticojejunostomy: A propensity score-matched study. Surgery 2018; 164:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zureikat AH, Postlewait LM, Liu Y, et al. A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. Ann Surg 2016; 264:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan Q, Xu LB, Ren ZF, Liu C. Robotic versus open pancreaticoduodenectomy: a meta-analysis of short-term outcomes. Surg Endosc 2020; 34:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jilesen AP, van Eijck CH, Busch OR, et al. Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. World J Surg 2016; 40:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azari FS, Vollmer CM Jr, Roses RE, et al. A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: Morbidity, mortality, and impact on future therapy. Surgery 2020; 168:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergeat D, Merdrignac A, Robin F, et al. Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial. JAMA Surg 2020; 155:e202291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javed AA, Teinor J, Wright M, et al. Negative Pressure Wound Therapy for Surgical-site Infections: A Randomized Trial. Ann Surg 2019; 269:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagedan DJ, Ahmed M, Devitt KS, Wei AC. Enhanced recovery after pancreatic surgery: a systematic review of the evidence. HPB (Oxford) 2015; 17:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JM, Kuo TC, Chen HA, et al. Randomized trial of oral versus enteral feeding for patients with postoperative pancreatic fistula after pancreatoduodenectomy. Br J Surg 2019; 106:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerritsen A, Besselink MG, Gouma DJ, et al. Systematic review of five feeding routes after pancreatoduodenectomy. Br J Surg 2013; 100:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He S, Xia J, Zhang W, et al. Prophylactic abdominal drainage for pancreatic surgery. Cochrane Database Syst Rev 2021; 12:CD010583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giglio MC, Spalding DR, Giakoustidis A, et al. Meta-analysis of drain amylase content on postoperative day 1 as a predictor of pancreatic fistula following pancreatic resection. Br J Surg 2016; 103:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassi C, Molinari E, Malleo G, et al. Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial. Ann Surg 2010; 252:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beane JD, House MG, Ceppa EP, et al. Variation in Drain Management After Pancreatoduodenectomy: Early Versus Delayed Removal. Ann Surg 2019; 269:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazanjian KK, Hines OJ, Eibl G, Reber HA. Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients. Arch Surg 2005; 140:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen PJ, Gönen M, Brennan MF, et al. Pasireotide for postoperative pancreatic fistula. N Engl J Med 2014; 370:2014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connor S, Alexakis N, Garden OJ, et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005; 92:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeng Q, Zhang Q, Han S, et al. Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas 2008; 36:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hesse UJ, DeDecker C, Houtmeyers P, et al. Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy. World J Surg 2005; 29:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alghamdi AA, Jawas AM, Hart RS. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Can J Surg 2007; 50:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shan YS, Sy ED, Tsai ML, et al. Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin. World J Surg 2005; 29:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-De la Medina A, Sarr MG. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. J Hepatobiliary Pancreat Surg 2006; 13:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suc B, Msika S, Piccinini M, et al. Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. Arch Surg 2004; 139:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarr MG, Pancreatic Surgery Group. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg 2003; 196:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev 2013; :CD008370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassi C, Butturini G, Molinari E, et al. Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig Surg 2004; 21:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg PK, Sharma J, Jakhetiya A, Chishi N. The Role of Prophylactic Octreotide Following Pancreaticoduodenectomy to Prevent Postoperative Pancreatic Fistula: A Meta-Analysis of the Randomized Controlled Trials. Surg J (N Y) 2018; 4:e182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma LW, Dominguez-Rosado I, Gennarelli RL, et al. The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial. Ann Surg 2017; 265:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunstman JW, Goldman DA, Gönen M, et al. Outcomes after Pancreatectomy with Routine Pasireotide Use. J Am Coll Surg 2019; 228:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young S, Sung ML, Lee JA, et al. Pasireotide is not effective in reducing the development of postoperative pancreatic fistula. HPB (Oxford) 2018; 20:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyder O, Dodson RM, Nathan H, et al. Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA Surg 2013; 148:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993; 217:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balcom JH 4th, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellegrini CA, Heck CF, Raper S, Way LW. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg 1989; 124:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987; 206:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kneuertz PJ, Pitt HA, Bilimoria KY, et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg 2012; 16:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birkmeyer JD, Warshaw AL, Finlayson SR, et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999; 126:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilimoria KY, Talamonti MS, Sener SF, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008; 207:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gooiker GA, van Gijn W, Wouters MW, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011; 98:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hata T, Motoi F, Ishida M, et al. Effect of Hospital Volume on Surgical Outcomes After Pancreaticoduodenectomy: A Systematic Review and Meta-analysis. Ann Surg 2016; 263:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beugniez C, Sauvanet A, Sulpice L, et al. Root-cause Analysis of Mortality After Pancreatic Resection (CARE Study): A Multicenter Cohort Study. Ann Surg 2021; 274:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rijssen LB, Zwart MJ, van Dieren S, et al. Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. HPB (Oxford) 2018; 20:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smits FJ, Henry AC, Besselink MG, et al. Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. Lancet 2022; 399:1867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traverso LW, Hashimoto Y. Delayed gastric emptying: the state of the highest level of evidence. J Hepatobiliary Pancreat Surg 2008; 15:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Berge Henegouwen MI, van Gulik TM, DeWit LT, et al. Delayed gastric emptying after standard pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: an analysis of 200 consecutive patients. J Am Coll Surg 1997; 185:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resnick J, Greenwald DA, Brandt LJ. Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part I. Am J Gastroenterol 1997; 92:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz M, O'Donovan D, Jones KL, et al. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002; 19:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butturini G, Daskalaki D, Molinari E, et al. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg 2008; 15:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 2017; 161:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai EC, Lau SH, Lau WY. Measures to prevent pancreatic fistula after pancreatoduodenectomy: a comprehensive review. Arch Surg 2009; 144:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cullen JJ, Sarr MG, Ilstrup DM. Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. Am J Surg 1994; 168:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Nakeeb A, Salah T, Sultan A, et al. Pancreatic anastomotic leakage after pancreaticoduodenectomy. Risk factors, clinical predictors, and management (single center experience). World J Surg 2013; 37:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham JA, Kayser R, Smirniotopoulos J, et al. Probability prediction of a postoperative pancreatic fistula after a pancreaticoduodenectomy allows for more transparency with patients and can facilitate management of expectations. J Surg Oncol 2013; 108:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh TS, Jan YY, Jeng LB, et al. Pancreaticojejunal anastomotic leak after pancreaticoduodenectomy--multivariate analysis of perioperative risk factors. J Surg Res 1997; 67:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts KJ, Sutcliffe RP, Marudanayagam R, et al. Scoring System to Predict Pancreatic Fistula After Pancreaticoduodenectomy: A UK Multicenter Study. Ann Surg 2015; 261:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loos M, Strobel O, Legominski M, et al. Postoperative pancreatic fistula: Microbial growth determines outcome. Surgery 2018; 164:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hank T, Sandini M, Ferrone CR, et al. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. JAMA Surg 2019; 154:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PARANOIA Study Group:, Writing group:, Halle-Smith JM, et al. Perioperative interventions to reduce pancreatic fistula following pancreatoduodenectomy: meta-analysis. Br J Surg 2022; 109:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malgras B, Duron S, Gaujoux S, et al. Early biliary complications following pancreaticoduodenectomy: prevalence and risk factors. HPB (Oxford) 2016; 18:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scholten L, Mungroop TH, Haijtink SAL, et al. New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis. Surgery 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AN, Pal S, Kilambi R, et al. Diabetes after pancreaticoduodenectomy: can we predict it? J Surg Res 2018; 227:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell DW, Jajja MR, Tariq M, et al. Development of Diabetes after Pancreaticoduodenectomy: Results of a 10-Year Series Using Prospective Endocrine Evaluation. J Am Coll Surg 2019; 228:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarzavadjian Le Bian A, Cesaretti M, Tabchouri N, et al. Late Pancreatic Anastomosis Stricture Following Pancreaticoduodenectomy: a Systematic Review. J Gastrointest Surg 2018; 22:2021.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 91408 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17457171" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hospital volume and late survival after cancer surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16192814" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Long-term survival is superior after resection for cancer in high-volume centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16794383" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : One thousand consecutive pancreaticoduodenectomies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12963649" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10982512" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Primary duodenal adenocarcinoma: a 40-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The Whipple operation: The classical surgical procedure to treat chronic pancreatitis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23890963" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Safety of perioperative aspirin therapy in pancreatic operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19464088" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : ESPEN Guidelines on Parenteral Nutrition: surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3890241" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Preoperative percutaneous transhepatic internal drainage in obstructive jaundice: a randomized, controlled trial examining renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2986562" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741850" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Preoperative endoscopic drainage for malignant obstructive jaundice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6372935" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6126752" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21037440" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20071702" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Preoperative biliary drainage for cancer of the head of the pancreas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17636818" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Endoscopic retrograde cholangiopancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972086" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pre-operative biliary drainage for obstructive jaundice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24264780" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28043693" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21750930" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9128996" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9667516" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Workup of a patient with a mass in the head of the pancreas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10365885" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : How accurate is helical computed tomography for clinical staging of pancreatic cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9168704" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9456949" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10579988" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19396496" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34851713" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19838756" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Vascular anomalies encountered during pancreatoduodenectomy: do they influence outcomes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19106685" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ischemic complications after pancreaticoduodenectomy: incidence, prevention, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20577144" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Influence of prophylactic probiotics and selective decontamination on bacterial translocation in patients undergoing pancreatic surgery: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37078771" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17726628" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Specific antibiotic prophylaxis based on bile cultures is required to prevent postoperative infectious complications in pancreatoduodenectomy patients who have undergone preoperative biliary drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22481442" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Selection of prophylactic antibiotics according to the microorganisms isolated from surgical site infections (SSIs) in a previous series of surgeries reduces SSI incidence after pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23992045" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of bacteriobilia decreases wound infection rates after pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33630442" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The Role of Targeted Versus Standard Antibiotic Prophylaxis in Pancreatoduodenectomy in Reducing Postoperative Infectious Complications: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26887853" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505267" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Incidence of venous thromboembolism and its effect on survival among patients with common cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21725687" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Timing of preoperative pharmacoprophylaxis for pancreatic surgery patients: a venous thromboembolism reduction initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30380143" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15529849" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Laparoscopic gastrojejunostomy for gastric outlet obstruction in pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17709731" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Accuracy of staging node-negative pancreas cancer: a potential quality measure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33471373" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19387741" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34353988" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28815556" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31304423" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Venous resection during pancreatectomy for pancreatic cancer: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32951905" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19630998" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Perioperative management in distal pancreatectomy: results of a survey in 23 European participating centres of the DISPACT trial and a review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23866787" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intraperitoneal drainage after pancreatic resection: a review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15570212" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27764898" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prophylactic abdominal drainage for pancreatic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9841995" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Is intra-abdominal drainage necessary after pancreaticoduodenectomy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21689234" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pancreatic resection without routine intraperitoneal drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23360918" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23521944" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Is it time to abandon routine operative drain use? A single institution assessment of 709 consecutive pancreaticoduodenectomies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11573042" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27513157" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : No Need for Routine Drainage After Pancreatic Head Resection: The Dual-Center, Randomized, Controlled PANDRA Trial (ISRCTN04937707).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24374513" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29928755" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prophylactic abdominal drainage for pancreatic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26905229" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17245171" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7632143" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15800958" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16201125" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10637702" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : [Gastrointestinal quality of life after duodenopancreatectomy in pancreatic carcinoma. Preliminary results of a prospective randomized study: pancreatoduodenectomy or pylorus-preserving pancreatoduodenectomy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15492552" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prospective randomized study to evaluate quality of life after partial pancreatoduodenectomy according to Whipple versus pylorus preserving pancreatoduodenectomy according to Longmire-Traverso for periampullary carcinoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Vergleich der partiellen Duodenopankreatektomie (Whipple operation) mit der pylorouserhaltenden Zephaloduodenopankreatektomie: eine prospektive kontrollierte, randomisierte Langzeitstudie
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885510" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pylorus Resection Does Not Reduce Delayed Gastric Emptying After Partial Pancreatoduodenectomy: A Blinded Randomized Controlled Trial (PROPP Study, DRKS00004191).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30671796" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Randomized Trial of Pylorus-Preserving vs. Pylorus-Resecting Pancreatoduodenectomy: Long-Term Morbidity and Quality of Life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8102817" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Gastric emptying and enterogastric reflux after conservative and conventional pancreatoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1354435" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7817989" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3964962" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21735323" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Preservation of the pyloric ring has little value in surgery for pancreatic head cancer: a comparative study comparing three surgical procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24619624" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A prospective randomized comparison between pylorus- and subtotal stomach-preserving pancreatoduodenectomy on postoperative delayed gastric emptying occurrence and long-term nutritional status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16327486" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7574936" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22744638" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Randomized controlled single-center trial comparing pancreatogastrostomy versus pancreaticojejunostomy after partial pancreatoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15910726" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A controlled randomized multicenter trial of pancreatogastrostomy or pancreatojejunostomy after pancreatoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16038822" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Pancreaticojejunal anastomosis is preferable to pancreaticogastrostomy after pancreaticoduodenectomy for longterm outcomes of pancreatic exocrine function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26135690" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23643139" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10759736" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Pancreaticojejunostomy versus pancreaticogastrostomy in reconstruction following pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24979604" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28898386" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16273533" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Duct-to-mucosa pancreaticogastrostomy is a safe anastomosis following pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21845376" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Dunking pancreaticojejunostomy versus duct-to-mucosa anastomosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7794068" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Optimal management of the pancreatic remnant after pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29575015" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Duct-to-mucosa versus dunking techniques of pancreaticojejunostomy after pancreaticoduodenectomy: Do we need more trials? A systematic review and meta-analysis with trial sequential analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35289922" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Duct-to-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17114014" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17717446" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22497024" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancreatic fistula after pancreaticojejunostomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21368658" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : External pancreatic duct stent decreases pancreatic fistula rate after pancreaticoduodenectomy: prospective multicenter randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27153248" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20717066" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Stenting versus non-stenting in pancreaticojejunostomy: a prospective study limited to a normal pancreas without fibrosis sorted by using dynamic MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12496531" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection: prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15531229" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32157697" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23601899" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A prospective, randomized trial of Roux-en-Y reconstruction with isolated pancreatic drainage versus conventional loop reconstruction after pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30507039" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Randomized trial of two types of gastrojejunostomy after pancreatoduodenectomy and risk of delayed gastric emptying (PAUDA trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9287993" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Evolution and current status of the Whipple procedure: an update for gastroenterologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25150551" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Successful treatment of recurrent cholangitis by constructing a hepaticojejunostomy with long Roux-en-Y limb in a long-term surviving patient after a Whipple procedure for pancreatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19918578" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Acute cholangitis due to afferent loop syndrome after a Whipple procedure: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21409601" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Effect of antecolic or retrocolic reconstruction of the gastro/duodenojejunostomy on delayed gastric emptying after pancreaticoduodenectomy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16495694" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19083149" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Prospective randomized controlled study of gastric emptying assessed by (13)C-acetate breath test after pylorus-preserving pancreaticoduodenectomy: comparison between antecolic and vertical retrocolic duodenojejunostomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24096769" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Antecolic versus retrocolic route of the gastroenteric anastomosis after pancreatoduodenectomy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24121364" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35014692" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23504140" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Robotic versus open pancreatectomy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26863398" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Minimally Invasive Versus Open Pancreatoduodenectomy: Systematic Review and Meta-analysis of Comparative Cohort and Registry Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29390259" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Minimally invasive surgical approach versus open procedure for pancreaticoduodenectomy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29169337" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Minimally invasive pancreaticoduodenectomy for periampullary disease: a comprehensive review of literature and meta-analysis of outcomes compared with open surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28895142" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30138162" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Comparison of Perioperative Outcomes Between Laparoscopic and Open Approach for Pancreatoduodenectomy: The PADULAP Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30685489" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25203880" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24154790" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Recent developments in surgery: minimally invasive approaches for patients requiring pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25761143" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30093277" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Comparison between robotic and open pancreaticoduodenectomy with modified Blumgart pancreaticojejunostomy: A propensity score-matched study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27433907" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31848756" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Robotic versus open pancreaticoduodenectomy: a meta-analysis of short-term outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26608956" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888713" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: Morbidity, mortality, and impact on future therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32667635" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31082899" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Negative Pressure Wound Therapy for Surgical-site Infections: A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24750457" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Enhanced recovery after pancreatic surgery: a systematic review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30724356" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Randomized trial of oral versus enteral feeding for patients with postoperative pancreatic fistula after pancreatoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23354970" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Systematic review of five feeding routes after pancreatoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34921395" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Prophylactic abdominal drainage for pancreatic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26791838" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Meta-analysis of drain amylase content on postoperative day 1 as a predictor of pancreatic fistula following pancreatic resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20622661" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29064899" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Variation in Drain Management After Pancreatoduodenectomy: Early Versus Delayed Removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16172293" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24849084" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Pasireotide for postoperative pancreatic fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16044410" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18192875" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16132406" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18053374" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16284796" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16708293" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15006886" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12691930" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23633353" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Somatostatin analogues for pancreatic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14707394" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Pancreatic fistula rate after pancreatic resection. The importance of definitions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30474064" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : The Role of Prophylactic Octreotide Following Pancreaticoduodenectomy to Prevent Postoperative Pancreatic Fistula: A Meta-Analysis of the Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27429029" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30414453" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Outcomes after Pancreatectomy with Routine Pasireotide Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30060910" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Pasireotide is not effective in reducing the development of postoperative pancreatic fistula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24108580" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8098202" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : One hundred and forty-five consecutive pancreaticoduodenectomies without mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11296108" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9339931" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2322039" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2742478" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3632096" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Improved hospital morbidity, mortality, and survival after the Whipple procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22760965" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Risk of morbidity and mortality following hepato-pancreato-biliary surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11948273" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Hospital volume and surgical mortality in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10455881" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Relationship between hospital volume and late survival after pancreaticoduodenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18926452" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645640" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Surgeon volume and operative mortality in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21500187" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26636243" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Effect of Hospital Volume on Surgical Outcomes After Pancreaticoduodenectomy: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34334643" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Root-cause Analysis of Mortality After Pancreatic Resection (CARE Study): A Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29571615" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35490691" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18535763" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Delayed gastric emptying: the state of the highest level of evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9328386" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Delayed gastric emptying after standard pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: an analysis of 200 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9149181" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11918620" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Gastric emptying in diabetes: clinical significance and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18535760" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Pancreatic fistula: definition and current problems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16003309" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Postoperative pancreatic fistula: an international study group (ISGPF) definition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28040257" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19917946" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Measures to prevent pancreatic fistula after pancreatoduodenectomy: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7524375" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23494109" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Pancreatic anastomotic leakage after pancreaticoduodenectomy. Risk factors, clinical predictors, and management (single center experience).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775846" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Probability prediction of a postoperative pancreatic fistula after a pancreaticoduodenectomy allows for more transparency with patients and can facilitate management of expectations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9073557" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Pancreaticojejunal anastomotic leak after pancreaticoduodenectomy--multivariate analysis of perioperative risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25371115" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Scoring System to Predict Pancreatic Fistula After Pancreaticoduodenectomy: A UK Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30217397" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Postoperative pancreatic fistula: Microbial growth determines outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31411659" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35727956" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Perioperative interventions to reduce pancreatic fistula following pancreatoduodenectomy: meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27037207" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Early biliary complications following pancreaticoduodenectomy: prevalence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29779868" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29804855" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Diabetes after pancreaticoduodenectomy: can we predict it?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30690075" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Development of Diabetes after Pancreaticoduodenectomy: Results of a 10-Year Series Using Prospective Endocrine Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29980974" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Late Pancreatic Anastomosis Stricture Following Pancreaticoduodenectomy: a Systematic Review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
